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ABSTRACT: This review summarizes the anticancer potential of fungal metabolites, highlighting the role of total 6 
synthesis in sustaining their pharmacological development as an alternative to isolation. This paper also outlines the 7 
feasibility of innovative synthetic procedures that facilitate the development of fungal metabolites into drugs that may 8 
become a real future perspective. This review demonstrates that total chemical synthesis is a fruitful means of yielding 9 
fungal derivatives as aided by recent technological and innovative advancements. 10 
 11 
1. Introduction  12 
 13 
Fungi are a well-known and valuable source of compounds of therapeutic relevance. They still are a relevant pool 14 
from which to search for new lead compounds in the pharmaceutical field. In the past, the drug industry has often 15 
centered on libraries of synthetic molecules as it attempts to discover active medical ingredients. However, recent 16 
research evolution clearly shows that natural compounds will be ever more important as a hotbed of new drugs in the 17 
future, even though the intrinsic complexity of discovering natural product-based drugs requires a deep network of 18 
interdisciplinary approaches. Fungi are well-known as a rather unexploited and endless source of novel anticancer 19 
compounds. Their structures and mode of action complement the huge amount of active compounds that are extracted 20 
from plants. Fungi produce many secondary metabolites with high chemical diversity and are still far from being 21 
exhaustively investigated. Notably, the long road that leads to a natural compound becoming a “marketed drug” goes 22 
hand in hand with the increasingly challenging necessity for producing higher amounts of compound. These can seldom 23 
be obtained through re-isolation from the respective natural tissues. Total organic synthesis is therefore still one of the 24 
most efficient alternatives to resupply. Furthermore, natural product total synthesis, in its most essential form, is a so-far 25 
unparalleled vehicle for discovery. In fact, thanks to almost unlimited natural diversity, natural compounds are 26 
distinguished by their peculiar three-dimensional structures and biological properties, which present incomparable 27 
research challenges. Efforts toward the synthesis of target natural compounds have increased knowledge of how to 28 
construct molecules and has led to innovative methodologies in enantioselective organic synthesis being developed. 29 
This review provides an overview of metabolites isolated from fungi, which exhibit anticancer activity against specific 30 
cell lines. This paper also outlines the feasibility of innovative synthetic procedures that allow the development of 31 
fungal metabolites into drugs that may become a real future perspective. The literature on metabolites isolated from 32 
fungi has recently been updated. In 2014, Nicoletti [1] published a comprehensive overview of fungal secondary 33 
metabolites with anticancer activity. He dealt with occurrence, selection, structural diversity and mechanisms. More 34 
recently, fungal metabolites with anticancer activity were excellently reviewed by Kiss[2] in 2014 and Kornienko and 35 
Evidente in 2015[3]. More specifically, secondary metabolites with anticancer activity isolated from endophytic fungi 36 
were reviewed by Zhang in 2011 [4] and by Kharwar and Stierle in 2014.[5] These reviews classified all the compounds 37 
according to their chemical structures. These recent and exhaustive publications have been used as a base from which 38 
we consider the synthetic feasibility of the most promising compounds, in terms of anticancer properties and drug 39 
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development. Furthermore, we extend the scope of our review to those compounds whose synthesis has been realized 1 
using unique and challenging synthetic strategies. In line with the aforementioned chemical reviews, compounds are 2 
herein classified according to their chemical structure, although some compounds may be included in different chemical 3 
classes. The timelines for the selected syntheses are extremely heterogeneous; while synthetic improvements are recent 4 
for some of the best-known and widespread compounds, for other classes of compounds, synthetic strategies date back 5 
further in time. To our knowledge, this review is the first effort to deal with the total synthesis of these active fungi 6 
metabolites. Our goal is to demonstrate that total chemical synthesis is a fruitful means by which to produce natural 7 
products and natural product derivatives, not only for those showing simple structures, but even for more complex 8 
structures with multiple chiral centers. Due to the massive number of fungal metabolites in existence, the compounds in 9 
this review should be seen as a selection of the most representative in terms of application potential. Those not taken 10 
into account in this review can be regarded as valuable material for re-evaluation in future publications. 11 
 12 
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2. ANTICANCER FUNGAL METABOLITES 26 
 27 
2.1 NITROGEN-CONTAINING COMPOUNDS 28 
Alkaloids are a very heterogeneous class of compounds. They are commonly contained in endophytic fungi where 29 
they show an important function as a defense against herbivores and insects. It is worth noting that some of the most 30 
important anticancer plant alkaloids have been isolated from endophytic fungi. The chemical structures of the alkaloids 31 
described in this review are reported in Figure 1. 32 
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Figure 1 Structures of the nitrogen-containing compounds discussed 2 
 3 
When discussing fungal anticancer metabolites, we cannot help but cite Vinblastine (1a Figure 1) and Vincristine (1b), 4 
which are the most widely known constituents of the Vinca alkaloid class, and Camptothecin (CPT 2, Figure 1).  5 
First introduced into the clinic over 50 years ago, 1a and 1b have provided one of the most important contributions that 6 
natural products have given to chemotherapy and are still nowadays efficacious clinical drugs used for the treatment of 7 
a wide range of cancerous diseases.[6] Originally isolated from Catharanthus roseus, they have also been found to be 8 
produced by some endophytic strains of Alternaria sp. and Fusarium oxysporum.[1] However, the main source of Vinca 9 
alkaloids is still plants, as a consequence an inclusive discussion of the most recent progresses in the synthesis of 1a and 10 
1b is out of scope of our overview. For very recent updates on the subject, please see Boger and Thomas’ reviews.[6-7] 11 
Camptothecin is a pentacyclic quinoline alkaloid that was initially isolated, in 1966 by Wall and co-workers [8], 12 
from the wood of Camptotheca acuminata (Nyssaceae), a plant native to Tibet and China (called ‘xi shu’ or ‘happy 13 
tree’). Historically, it has been widely-known for its therapeutic properties. In 2005, the compound was also isolated 14 
from an endophytic fungus Entrophospora infrequens that is found in an antitumor plant Nothapodytes foetida in the 15 
Western coast of India.[9] Initial human clinical studies were complicated by CPT’s poor solubility in water, high 16 
toxicity and rapid inactivation, caused by E ring hydrolysis under physiological conditions, that restrict its therapeutic 17 
applications. Interest in CPT was renewed by the discovery of its peculiar property of inhibiting DNA topoisomerase I 18 
[10] leading to numerous CPT derivatives being synthesized in an attempt to obtain more soluble and stable compounds 19 
over the last 2 decades. This effort yielded two semi-synthetic CPT analogues that have been clinically approved by the 20 
FDA, namely Irinotecan (sold by Pfizer as Camptosar®, against metastatic colorectal carcinoma) and Topotecan 21 
(produced by GlaxoSmith-Kline as Hycamtin®, for the treatment of ovarian and small-cell lung cancer).  22 
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An exhaustive dissertation on the syntheses of CPT and its derivatives lies outside the focus of this review as CPT is a 1 
typical plant metabolite presumably isolated by fungi because of horizontal gene transfer. However, research studies 2 
into camptothecin total synthesis, structure–activity relationship, mechanism of action, pharmacology, pre-clinical 3 
studies and clinic trials have recently been widely discussed in several excellent reviews.[11]     4 
 5 
2.1.1 Phenylahistin (3)  6 
2,5-Diketopiperazines (DKPs 3-6 Figure 1) present a typical six-membered heterocyclic ring containing two 7 
nitrogen atoms in opposite positions (C1,C4), which is usually biosynthesized through the condensation of two α-amino 8 
acids. DKPs have been isolated from Aspergillus and Penicillium species and are characterized by a wide range of 9 
bioactivity and have proven themselves to be important sources for drug development.[12] 10 
(-)-Phenylahistin (3 Figure 1) and related derivatives have exhibited strong growth inhibition in various tumor 11 
cell lines because of their strong binding affinity for microtubules.[3, 13] [14] [15] It was isolated from Aspergillus 12 
ustus as a racemic mixture by Kanoh et al. in 1997. [16] Its chemical structure includes an L-phenylalanine and a (Z)-13 
isoprenylated dehydrohistidine residue with a quaternary carbon at the 5-position of the imidazole ring. The more potent 14 
enantiomer (-)-phenylahistine acts at the colchicine binding site on tubulin and exhibits cytotoxic activity against a wide 15 
range of tumor cell lines in both in vitro and in vivo tests.[3, 13] Its semisynthetic analogue, Plinabulin (NPI-2358), is 16 
progressing to phase 3 trials on patients with non-small cell lung cancer (NSCLC).[12] An interesting structure−activity 17 
relationship study of phenylahistine derivative antimicrotubule agents was reported in 2012 by Yamazaki and co-18 
workers.[17] However, the total syntheses of natural (-)-phenylahistine is a useful tool with which to shed light on its 19 
biological activity and to aid the design of new diketopiperazine-structure-based anticancer drugs.  20 
In 2000, Hayashi et al. achieved the total synthesis of (-)-phenylahistin in which the key steps were the formation of the 21 
isoprenylated imidazole from ethyl isobutyrate and its condensation with the diketopiperazine derivative.[14] The total 22 
yield of the final enantiopure (-)-3 was unfortunately very low (1%). 23 
Two research groups later developed an alternative synthetic pathway to the dehydroamino acid moiety using a Horner–24 
Emmons type coupling between a phosphinyl glycine ester and a formylimidazole as the key step.[18] In 2005, 25 
Couladouros and Magos prepared (-)-phenylahistine in high yields (47% overall for four steps) and high optical purity 26 
using this approach.[18a] Their efforts were especially aimed at seeking synthetic approaches that are amenable to 27 
solid-phase application and led to the development of the unique solid-phase total synthesis of (-)-phenylahistin, which 28 
was based on the Horner–Emmons reaction (Scheme 1).[18b] Extended Merrifield resin was coupled with known acid 29 
20 to give the key solid supported glycine phosphonate 21, whose coupling was performed with the N-protected L-30 
amino acid Boc-L-Phe-OH. The mild Horner–Emmons conditions were applied to resin 22 to load the imidazole 31 
moiety. This methodology is a useful tool for the solid-phase synthesis of dehydro-2,5-diketopiperazines as it enables 32 
the rapid parallel synthesis of a large number of diversified structures. 33 
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Scheme 1 Couladouros and Magos’ solid-phase synthesis of (-)-phenylahistin: a) Merrifield resin, 1,4-butanediol, NaH, 2 
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    5 
2.1.2 Tryprostatin A (4a) and B (4b)  6 
In 1995, Osada’s group reported the isolation of Tryprostatin (TPS) A and B (4a and 4b Figure 1) from a marine 7 
strain (BM 939) of Aspergillus fumigatus. The TPS dikepiperazine scaffold derives from tryptophan and proline with a 8 
prenylated indole moiety. Both natural compounds are cell cycle inhibitors at the G2/M phase barrier with TPS B being 9 
more potent than A. Furthermore, TPS A was found to be an inhibitor of the breast cancer resistance protein.[19] [20] 10 
Most of the TPS A and B syntheses published before 2005 have been reviewed by Maison.[21] We herein update the 11 
recent developments in the total syntheses of TPS A and B. Recent syntheses of TPS analogues were reported by 12 
Stanovnik et al. and De Kimpe at al. in 2008 and 2013, respectively.[20, 22] A useful SAR study into the cell cycle 13 
inhibitory effects of TPS analogues and their potential antitumor antimitotic agents has been carried out by Cook et 14 
al.[23], who also accomplished the synthesis of TPS A and B enantiomers and diastereomers using already-known 15 
methods.[23] In 2000, Lobo and co-workers applied the pericyclic aza-Cope reaction to the asymmetric synthesis of 16 
TPS B for the first time. Full details of this work, which involved an acid-catalyzed rearrangement of an appropriately 17 
substituted tryptophan, were described in 2006 by the same research group.[24] Fukuyama’s group has developed three 18 
different syntheses for the 2-prenyl tryptophan core of tryprostatins along with their total syntheses,[25] but only the 19 
one we report in Scheme 2 is worthy of attention.[25-26] The key step in this strategy is the selective radical-mediated 20 
cyclization of isocyanide 24 that, along with a palladium-mediated coupling with a prenyl-group donor, lead to the 21 
facile construction of the di-substituted indole core 23. Isocyanide 24 was obtained from alkyne 25, which in turn was 22 
synthetized via the Sonogashira coupling of the terminal alkyne 26 with the aromatic iodide 27. In order for the final 23 
molecule to be obtained in high enantiomeric purity, alkyne 26 which was derived from Garner’s aldehyde 28, was used 24 
as a latent amino acid unit to be included in the diketopiperazine skeleton.  TPS B was synthesized in 11 steps (from 28) 25 
in a 33% overall yield and TPS A in a 30% overall yield using this approach (from 26 both on a half-gram scale). 26 
Unfortunately, this procedure is not eco-friendly and it is rather unsuitable for the industrial production of potential 27 
drugs as it involves toxic stannyl derivatives in the radical-mediated indole synthesis and uses highly toxic triphosgene 28 
as a reagent to obtain isocyanide 24.  29 
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Scheme 2 Fukuyama’s group strategy for the synthesis of TPS A and B. 2 
 3 
2.1.3 Fumitremorgin C (5a) and Demethoxyfumitremorgin C (5b) 4 
Together with TPS A and B, Osada’s group identified plausible biogenetic derivatives fumitremorgin C (FTC 5a 5 
Figure 1) and demethoxyfumitremorgin C (DFTC 5b) from the fermentation broth of Aspergillus fumigatus 6 
BM939.[27] They have recently been isolated from Aspergillus sydowi.[28] Both FTC and DFTC have proved to be 7 
inhibitors of mammalian cell cycle, like TPS A and B.[27]  8 
A complete review of the synthesis of Fumitremorgins was presented by Hino and Nagakawa in 1997.[27a] One of the 9 
most straightforward ways to build FTC and DFTC key intermediates, 29, makes use of the Pictet–Spengler reaction 10 
that involves the acid-catalyzed intramolecular condensation of an iminium ion and an aromatic C-nucleophile. After 11 
1997, Ganesan [27b, 29] and Bailey [30] devised new total syntheses of DFTC and FTC, respectively, exploiting this 12 
approach. Nevertheless, Ganesan’s procedure led to a mixture of diastereomers. By contrast, Bailey et al. managed to 13 
develop a diastereoselective three-step synthesis of enantiopure DFTC in a 21% overall yield (Scheme 3). His route 14 
furnished tetrahydro-β-carboline derivative 29 with 6:1 cis selectivity. 15 
 16 
N
H
COOMe
NH2
a CHO b
N
H
NH
COOMe
+
N
H
NH
COOMe
N COCl
Fmoc
N
H
N
COOMe
O
N Fmoc
H
c
DFTC
 
5b
29
N
H
COOMe
N
 17 
Scheme 3 Bailey’s synthesis of enantiopure DFTC: a) 3Å molecular sieves; b) CHCl3, TFA (38%); c) Piperidine, DMF 18 
(58%).  19 
8 
 
 1 
Later, in 2012, Jia and co-workers [31] applied a new Mg(ClO4)2-catalyzed intramolecular allylic amination reaction to 2 
give the tetrahydro-β-carboline skeleton in a 1:1 cis:trans ratio and then finished the total synthesis of DFTC from the 3 
cis-isomer. Enantiopure DFTC was obtained in a 24% overall yield in six steps, starting from N-Boc protected 4 
tryptophan.    5 
 6 
2.1.4 Fructigenin A (6), Ardeemin (7a) and N-Acetylardeemin (7b)  7 
(-)-fructigenine A (6 Figure 1) contains both a 2,5-diketopiperazine ring and a 3-substituted hexahydropyrrolo[2,3-8 
b]indole. This framework bears a 1,1-dimethylallyl (“reverse-prenyl”) group and is a widely distributed structural unit 9 
featuring several biologically active alkaloids, such as (-)-ardeemin and 5-N-acetylardeemin (7a and 7b Figure 1). 10 
(-)-Fructigenine A were isolated from Penicillium fructigenium by Kunizo et al. and showed growth-inhibitory activity 11 
against leukemia L-5178Y cells.[32] Ardeemins 7 were isolated from Aspergillus fischerii by McAlpine and co-workers 12 
[33] and demonstrated a potent ability to reverse multi-drug resistance (MDR).[34] N-acetylardeemin, in particular, is 13 
one of the most potent known inhibitors of MDR to antitumor agents, such as vinblastine and taxol.[34]  14 
Recent advances in the synthesis of enantiopure (-)-ardeemin have already been cited in Yong Qin et al. 15 
(2009)[34] and also reported in Alvarez group’s review (2011).[35]  16 
In 2010, Kawasaki et al. managed to achieve the first asymmetric total synthesis of 6 and a new synthetic pathway for 17 
7b via an imine derivative 30 (Scheme 4).[36] The synthetic route involves an Ugi three-component reaction of 30 with 18 
the corresponding amino acid and isonitrile followed by cyclization to construct the pyrazino ring. The pyrroloindoline 19 
imine 30 is obtained via the regioselective oxidation of enantiomerically enriched pyrroloindoline 31, which is readily 20 
prepared by an asymmetric olefination/isomerization/Claisen rearrangement (OIC) and reductive cyclization (RC). (-)-21 
Fructigenine A was obtained in four steps and in a 45% overall yield from imine 30. (-)-5-N-acetylardeemin was 22 
achieved in a 37.6% three-step yield from the same common intermediate which, in turn, was produced after ten steps 23 
and in a 26.5% overall yield with high enantiomeric purity (99% ee).  24 
 25 
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Scheme 4 Kawasaki’s approach for synthetizing enantiopure 6 and 7b 27 
 28 
A new total synthesis of (-)-ardeemin and (-)-acetylardeemin was published by Qin’s group in 2012 (Scheme 5).[37] 29 
The key step was a silver-promoted Friedel-Crafts reation to achieve the direct isoprenylation of bromopyrroloindoline 30 
32 with prenyl tributylstannane. (-)-Formylardeemin 33 was obtained from 32 in a 36% overall yield in 8 steps. 7a was 31 
readily prepared from 33 via simple deformylation and 7b was prepared from 7a by a single step of acetylation. The 32 
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highly efficient installation of the isoprenyl group on the pyrroloindoline skeleton greatly enhanced synthetic efficiency 1 
and made the whole procedure a practical tool for the large-scale synthesis of 7a and 7b, except for the fact that it 2 
includes the use of a toxic stannane.   3 
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 10 
2.1.5 Neoxaline (8) and Oxaline (9)  11 
Neoxaline (8 Figure 1) and structurally related oxaline (9) are biologically active prenylated indole alkaloids that 12 
bear an indoline spiroaminal structure with a “reverse prenyl” group and a (E)-dehydrohistidine moiety (Figure 1).[38] 13 
Oxaline families were isolated from Penicillium spp. and found to exhibit moderate antibacterial, antifungal and 14 
anticancer activities.[38] Ōmura and co-workers isolated Neoxaline from a culture broth of Aspergillus japonicas in 15 
1979.[38] Neoxaline was found to inhibit cell proliferation and arrest cell cycles during the M phase. Both 8 and 9 were 16 
found to be inhibitors of tubulin polymerization.[38a] Only Ōmura and co-workers have successfully carried out the 17 
total synthesis of neoxaline family alkaloids. They initially established neoxaline as their synthetic target and reported 18 
the construction of the indoline spiroaminal framework in 2005.[38a] Afterwards, but only in 2013, did they manage to 19 
accomplish the first asymmetric total synthesis of 8 (Scheme 6) and the determination of its absolute 20 
configuration.[38b] Pivotal steps in the synthesis were: i) the stereoselective introduction of the reverse prenyl group at 21 
the benzylic ring junction via treatment with prenyl tributylstannane to give (3aR,8aS)-34 as a single diastereomer; ii) 22 
the preparation of cyclization precursor 36, involving the boric acid-mediated addition of isocyanoacetate 35; iii) the 23 
construction of indoline spiroaminal (9R)-37 via three oxidations and two cyclizations from indoline 36; iv) the 24 
insertion of the conjugated imidazole at C12 using an aldol reaction of imidazolyl aldehyde 38; v) the final 25 
photoisomerization of unnatural (Z)-neoxaline 39 using mercury lamp irradiation to obtain natural (E)-neoxaline.  26 
10 
 
N
H
OH a-c Bu3Sn
d N
Alloc
O
N
O
O
H
HN
CCl3
Alloc
H
3aR
8aS
34
e-h
N
Alloc
H
O
i
OMe
O
N
35
N
Alloc
OH
HN
O
MeO O
j
k N N
O
OO
N
H
OTBS
HN
O
MeO O
l
N
H
OTBS
HN
O
H2N O
36
9R9R
m
N
OTBS
HN
O
H2N O
9R
O
+
N
OH
N
H
OTBS
O
O
H2N
n
o,p
N
HO
N
OTBS
O
HN
O
37
9R
q,r
N
TBSO
N
OTBS
O
N
OSEM
12
s
38
N
Boc
NO
N
TBSO
N
OTBS
O
N
OSEM
OH
N
Boc
N
t-w
N
H3CO
N
OTBS
O
HN
O
NH
N9S x
N
H3CO
N
OH
O
HN
O
NH
N
39
y 8
z
 1 
Scheme 6 Ōmura’s first asymmetric total synthesis of 8: a) t-BuOOH, (+)-DITP, Ti(O-i-Pr)4, DCM (99%, 99% ee); b) 2 
Alloc-Cl, NaHCO3, DCM, H2O (94%); c) Cl3CCN, DBU, DCM (quant.); d) BF3·OEt2, DCM (87%); e) Pd(PPh3)4, 3 
dimedone, MeOH (98%); f) NaBH(OAc)3, AcOH, DCE (88%); g) Alloc-Cl, NaHCO3, DCM, H2O (97%); h) Dess 4 
Martin periodinane, DCM (quant.); i) B(OH)3, DMF (91%); j) TBSOTf, 2,6-lutidine, DCM (quant.); k) Pd(PPh3)4, THF 5 
(83%); l) 2M NH3 in MeOH (99%); m) Na2WO4·2H2O, H2O2·urea, MeOH, H2O; n) Et3N, benzene (93%, two steps); o) 6 
Pb(OAc)4, DCM (96%); p) TBAOH, DCM (93%); q) TBSOTf, DIPEA, DCM (98%); r) SEMCl, NaH, THF (97%); s) 7 
LiHMDS, THF (59%); t) EDC, CuCl2, toluene (76%); u) TBAF, THF (88%); v) MeI, K2CO3, DMF (86%); w) Me3Al, 8 
DCM (71%); x) HF·pyridine (73%); y) hν (λ < 325 nm), MeOH (55%).  9 
 10 
In 2015, Ōmura’s group published an improved asymmetric total synthesis of 8, in which was accomplished the direct 11 
stereoselective construction of (E)-dehydrohistidine.[38c] This new synthesis of neoxaline led the overall yield to 7.9% 12 
yield in 24 steps and allowed more than 300 mg of final product to be prepared. In the same article, the first total 13 
synthesis of oxaline was also described, although it was via a slightly modified synthetic route.[38c]   14 
 15 
2.1.6 Gliotoxin (10) 16 
Epipolythiodioxopiperazines (ETPs, 10-14 Figure 1) have attracted considerable attention thanks to their potent 17 
anticancer activity. They are fungal metabolites that possess peculiar architectures with a polysulfide bridge onto a 18 
diketopiperazine six membered ring. They can present a monomeric (10, 11 and 14 Figure 1) or a dimeric scaffold (12 19 
and 13 Figure 1) and are characterized by great activities against parasites, viruses, bacteria and cancer cells.[39] For a 20 
brief collection of the methods for the building of the polysulfide bridges of ETPs, see ref. 40 and references 21 
therein.[40] 22 
11 
 
Gliotoxin (10 Figure 1), which is produced by various species of Gladiocladium, Trichoderma, Aspergillus and 1 
Penicillium, [1, 41] belongs to the ETPs class as it is based on tryptophan and a single dithiodioxopiperazine moiety. In 2 
the 1970s, Kishi’s group managed to accomplish the first total synthesis of 10 by masking the 3,6-3 
dithiodiketopiperazine core with anisaldehyde and then generating the desired epidithiodiketopiperazine at a later stage. 4 
[41]  5 
Since then no great effort had been made to carry out the enantioselective synthesis of this compound, until 2012 when 6 
Nicolaou and co-workers obtained enantiopure gliotoxin. Nicolaou’s strategy passed through bicyclic hydroxy diene 42 7 
which was obtained in multigram quantities from tyrosine-derived 40 (Scheme 7). The nine-step sequence is 8 
noteworthy for its use of the [4+2] photooxygenation of diene 41 to generate a hydroxyl endoperoxide. 10 was then 9 
prepared from 42 via five synthetic steps, involving the crucial final sulfenylation of 43, which was based on the use of 10 
LiHMDS and elemental sulfur in THF at 25°C. A sulfenylation step also furnished gliotoxin G as a side product in a 11 
33% yield. In the end, Nicolaou’s synthesis furnished 10 with in an overall yield of around 7%.   12 
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Scheme 7 Nicolaou’s asymmetric synthesis of 10: a) NaBH4, CeCl3·7H2O, MeOH (99%); b) Ac2O, Et3N, 4-DMAP, 14 
DCM (91%); c) Pd(OAc)2, PPh3, Et3N, toluene (86%); d) O2, TPP, hν, DCM (73%); e) MeOH (84%); f) TIPSOTf, 15 
Et3N, DCM (96%); g) (im)2C=S, toluene (90%); h) P(OMe)3 (82%); i) HCl, DCM/Et2O (98%); j) aq LiOH /THF 16 
(99%); k) HOAt, HATU, DIPEA, DCM (88%); l) TFA/DCM; m) Et3N/THF (63% two steps); n) LiHMDS 1.0 M in 17 
THF, S8 then LiHMDS (23%). 18 
 19 
2.1.7 Leptosin D (11a) and T988C (11b) 20 
Many ETP toxins possess a hydroxyl substituent at C11 of the pyrrolidine ring and a C10b quaternary stereo center. 21 
Leptosin D and T988C (11a and 11b, Figure 1) belong to this group and Overman and co-workers developed a common 22 
12 
 
strategy for preparing both of them in 2013.[39a] Central to their synthetic strategy (Scheme 8) was the α-ketoimide 1 
carbonyl and alkylidene double bond unit of Boc-gliocladin 45, prepared via the convergent gram-scale coupling of 2 
enantioenriched pro-dielectrophile 46 with pro-dinucleophile isatin 47. Further crucial steps in the total syntheses were: 3 
i) the introduction of C3 substituents via the chemoselective addition of an appropriate organometallic reagent to the C3 4 
carbonyl group of 45; ii) the stereoselective dihydroxylation of the C11−C11a double bond; iii) the stereoselective 5 
construction of the disulfide bridge via the BF3•OEt2-promoted reaction of H2S with the displacement of the oxygen 6 
substituents (acetoxy or siloxy) at C3 and C11a of precursor 44. The (+)-45 intermediate was obtained from 47 via a 7 
ten-step route with a 15% overall yield. Moreover, the divergent sequences developed in Overman’s work for preparing 8 
the target ETP compounds (6−9 steps, 14−33% yield) supplied plentiful quantities of 11a and 11b, which were used for 9 
in vitro cytotoxicity evaluations which demonstrated that the disulfide motif was required for the activity of these 10 
ETPs.[39a] 11 
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 14 
Moving to dimeric ETP natural alkaloids, (+)-12,12´-dideoxyverticillin A (12, Figure 1)  and (+)-chaetocins (13, Figure 15 
1) have been the most intensely investigated. Movassaghi’s ground breaking study on the biogenetically inspired 16 
syntheses of these compounds is a remarkable central intellectual construct toward the development of new syntheses 17 
for dimeric ETPs.[39c, 42] Highly cytotoxic 12 and 13 were isolated from marine Penicillium sp. [43] and the fungi of 18 
the Chaetomium genus [44], respectively. Since 2009, when Movassaghi and Kim published their pioneering total 19 
synthesis of 12 in Science, several enantioselective total syntheses of dimeric ETPs have been accomplished [39a] In 20 
this case, one more difficulty arises from the dimeric structure connected with a chiral quaternary carbon. As 21 
Movassaghi’s work on 12, including his enantioselective synthesis of (+)-Chaetocins A 13a and B 13b, has already 22 
been widely reviewed,[39c, 42, 45] we only wish to bring a few points to mind in this review. In 2009, Movassaghi [43] 23 
reported the first total synthesis of (+)-12,12´-dideoxyverticillin A 12 and Sodeoka [44a] accomplished the total 24 
synthesis of (+)-chaetocin A 13a in 2010. They both used 3,6-dihydroxyDKP and H2S to construct the ETP motif. Later 25 
in 2010, Movassaghi’s group described the use of potassium trithiocarbonate (K2CS3) to generate an ETP moiety from a 26 
monosilylated 3,6-dihydroxyDKP intermediate in order to obtain 12 and 13.[44b] Moreover, Movassaghi performed the 27 
13 
 
key dimerization step by making use of cobalt-base chemistry and developing an effective multigram scale synthesis to 1 
simultaneously join the two vicinal C3 and C3’ quaternary stereocenters.[39c, 42] This synthetic shrewdness led to a 2 
high level of stereochemical control and chemoselectivity in the sulfidation of dimeric ETP intermediates. 3 
 4 
2.1.8 (+)-MPC1001B (14) 5 
Fungal metabolites, called MPC1001, isolated from a strain of Cladorrhinum sp. [1], display a wide range of 6 
anticancer activities, such as antiproliferative and apoptosis-inducing activity toward colon and prostate cancer cell 7 
lines.[46] These ETPs are characterized by a unique seven-member dihydrooxepine and a characteristic 15-membered 8 
ring which make their production achievement very difficult. Tokuyama group’s total synthesis of (+)-MPC1001B (14 9 
Figure 1), published in 2016 for the first time, therefore deserves to be mentioned.[46b] The conceived synthetic 10 
pathway is summarized in Scheme 9. Macrocycle 48 was built by exploiting an intramolecular aldol reaction to form 11 
the C3-C7” bond and two consecutive acyl condensations. The final synthetic step was sulfenylation accomplished via 12 
stepwise trityl trisulfide (TrSSS)-group transfer. The overall yield was only about 3% for 14 steps because of the 13 
multistep sulfenylation, which did not prove to be very efficient.  14 
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Scheme 9 Tokuyama’s synthesis of (+)-MPC1001B: a) BOP-Cl, Et3N, DCM (95%); b) Et3SiH, cat. Pd(OAc)2, cat.Et3N, 18 
DCM (94%); c) TBAF, THF (97%); d) cat. nor-AZADO, PhI(OAc)2, DCM (86%); e) NaBH4, CeCl3·7H2O, 19 
DCM/EtOH, (93%); f) WSCD, cat. DMAP, DCM (quant); g) TBAF, THF (71%); h) cat. AZADO, PhI(OAc)2, DCM, 20 
pH 7.4 phosphate buffer (79%); i) LiHMDS, TrSSSCl, THF three consecutive treatments (overall 22%); j) NaBH4, 21 
CeCl3·7H2O, DCM/EtOH, (quant); k) HSCH2CH2SO3Na, cat. DIPEA, DMF/H2O, RT; l) O2, AcOEt/MeOH (33% two 22 
steps).  23 
 24 
2.1.9 (-)-Communesin F (15) 25 
14 
 
Communesins are a motley family of alkaloids derived from various marine and terrestrial Penicillium fungi that 1 
possess antiproliferative activity and significant cytotoxicity against lymphocytic leukemia.[47] Recent advances in the 2 
total synthesis of this class of compounds have been fully and deeply examined by Trost [47a] and Ma et al. [47b] in 3 
their accounts, both published in 2015. Herein, we simply wish to highlight the very latest progress in this field, which 4 
is well represented by the first convergent and biomimetic synthesis of (-)-communesin F (15 Figure 1) reported by 5 
Movassaghi et al. in 2016.[48] The core of the whole synthesis strategy (Scheme 10) is made up of: i) an expedient 6 
diazene-based assembly for directed advanced fragments linkage to sew the C3a−C3a’ bond leading to complex 7 
sulfamide 49, in three steps on a gram scale; ii) the subsequent guided biomimetic aminal rearrangement that selectively 8 
yielded the heptacyclic communesin core in only three additional steps. Both the versatile syntheses of the two initial 9 
fragments [48], their stereo-controlled assembly and the final acylation of the communesin core have succeeded in 10 
providing a unified synthetic tool for the construction of structurally related complex alkaloids.  11 
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Scheme 10 Key steps in Movassaghi’s biomimetic strategy for synthetizing (-)-Communesin F 15: a) 4-(N,N-14 
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(67%); e) t-BuOLi, MeOH; dry PPTS, Ac2O (82%; f) Na(Hg), NaH2PO4, THF, MeOH (83%). 17 
 18 
2.1.10 (-)-Chaetominine (16) 19 
Ten years ago, in 2006, (-)-chaetominine (16 Figure 1) was isolated by Tan et al. from a solid-substrate culture of 20 
Chaetomium sp. IFB-E015 [49], an endophytic fungus on Adenophora axilliflora leaves, and from the metabolites of 21 
Aspergillus sp. HT-2.[50] It has exhibited potent cytotoxicity against human leukemia K562 and colon cancer cell 22 
SW1116 lines.[49] 16 is a modified tripeptide alkaloid which derives from Tryptophan, L-alanine, anthranilic acid and 23 
formic acid. Its peculiar structure is characterized by a tetracyclic core, containing four stereocenters and a 24 
quinazolinone segment. Owing to this fascinating architecture and its potential biological profiles, a great deal of 25 
synthetic effort has been focused on its total synthesis. Soon after its isolation, in 2007, a first total of 16 was published. 26 
For a concise case history on the enantioselective syntheses of (-)-chaetominine, from then to 2009, see reference 51 27 
[51] and the papers cited therein. In this review, we focus our attention on the new and shorter syntheses reported by 28 
15 
 
Huang and coworkers in 2014.[51a, 52] In their first paper, they disclosed the absolute shortest synthesis to date with 1 
the highest overall yield [52a] where 16 is achieved in four steps with an overall yield of 33.4% from D-tryptophan 2 
(Scheme 11). Pivotal features of this bio-inspired strategy involve: i) the use of a nitro group as a latent amino group for 3 
the one-pot construction of the quinazolinone system; ii) a one-pot transformation of intermediate 50 through a cascade 4 
indole epoxidation - amidative cyclization - lactamization reaction sequence to ensure C/D ring closure. Although the 5 
yield of 16 from 50 is modest, the strategy is highly efficient (three one-pot reaction) and also avoids the use of 6 
protecting groups. C3/C14 syn-selection occurs during the cascade sequence but β-epoxide is predominately formed 7 
followed by the base-promoted epimerization at C14 of compound 51 to compound 52. Taking advantage of these 8 
results, still in 2014, Huang et al. managed to accomplish an unprecedented bio-mimetic total synthesis of 16 from the 9 
suggested biosynthetic parent L-tryptophan.[51a] They thus proved that L-tryptophan, o-nitrobenzoyl chloride, L-10 
alanine and anthranilic acid can be assembled in five steps to give 16 in an overall yield of 23.2%. Based on these 11 
findings, a plausible biosynthetic pathway for 16 was then suggested [52b] and a comprehensive investigation was 12 
carried out to clarify the stereochemical requirements for the double cyclization and clarify the  physical and chemical 13 
properties of 16.[52b] 14 
 15 
COOH
NH
D-Trp
Cl
O
NO2
a
N
H
O NO2 MeO
O
NH2
Me
HCl
b
NH
N
H
O NO2
HN
O
O
MeO
Me
c N
N
H
O N
HN
O
O
MeO
Me
d
Epoxidation triggered 
cascade bis-cyclization 
reaction
50
N
N
H
O N
N
O
OMe
O
Me
O
H
1
2
3
a-epoxide : b-epoxide = 47 : 53
N
N
H
O
N
N O
OH
H
3 14
Me
O
MeO
+
N
N
H
O
N
N O
OH
H
3 14
Me
O
MeO
51
(3%) (51%)
N
N
O
N
N O
OH
H
3 14
(-)-Chaetominine
  
16
+
(42%)
O Me
e
N
N
O
N
N O
OH
H
3 14
O Me
52
 16 
 17 
 18 
Scheme 11 Huang’s four-step total synthesis of (−)-Chaetominine: a) 1M NaOH, THF (90%); b) ClCO2, i-Bu, NMM 19 
(91%); c) HC(OMe)3, Zn/TiCl4, THF (97%); d) DMDO, DMSO, acetone; e) NaOMe, MeOH (90%) or NBS, NaOMe, 20 
MeOH (40% unoptimized). 21 
 22 
2.1.11 Penicillenols (17, 18) 23 
Penicillenols (17 and 18 Figure 1) were isolated from Penicillium sp. GQ-7, an endophytic fungus associated with 24 
Aegiceras corniculatum.[53] They are pyrrolidine-2,4-dione derivatives (tetramic acid) bearing an a-methyl branched 25 
C8-fatty acyl residue at C-3. Penicillenol A1 17 and B1 18a have exhibited inhibitory activity against cell lines of HL-60 26 
leukaemia [53]. Both Penicillenol B1 18a  and B2 18b have shown equal activity against highly invasive 518A2 27 
melanoma [54] and cisplatin-resistant HT-29 colon carcinoma.[54] Firstly, Yoda and co-workers presented a 28 
stereoselective synthesis of Penicillenols A1 (17 Scheme 12) in nine steps from N,O-protected L-threonine with 29 
Meldrum’s acid and the subsequent 3-acylation of the so-formed tetramic acid.[55] The pivotal step of the synthesis 30 
was the improved O- to C-acyl rearrangement of a 4-O-acyltetramic acid derivative using CaCl2 as an effective additive 31 
for the formation of the 3-acyltetramic acid bearing a α-methyloctanoyl moiety. Recently, in 2015, Schobert’s group 32 
reported the first synthesis of 18a and 18b in 14 steps by employing an alternative, but longer (10 steps) pathway for the 33 
16 
 
tetramic acid core.[54] The correct configurational assignment of the natural products was carried out by comparing the 1 
NMR and optical rotation data of the synthetic products and it was found to be 5S,6R,9S for Penicillenol A1 17 [55a] 2 
and 9S for Penicillenols B 18a and 18b.[54] 3 
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 Scheme 12 Strategy for the first total stereoselective synthesis of Penicillenol A1  6 
 7 
2.1.12 Phaeosphaeride A (19) 8 
Phaeosphaeride A (19 Figure 1) was isolated from the endophytic fungus FA39 (Phaeosphaeria avenaria) by 9 
Clardy’s group in 2006.[56] It is an inhibitor of the signal transducer and an activator of transcription 3 (STAT3)-10 
dependent signaling.[57] Since 2011, several research groups have synthesized phaeosphaeride A.[58] All the syntheses 11 
developed focused on obtaining phaeosphaeride A with the proposed structure, 53 (Figure 2). However, NMR data for 12 
synthetic compounds were not identical to those of the natural product, indicating that the initially proposed structure of 13 
natural phaeosphaeride A was incorrect. In 2015, Kogen et al. finally established the correct configuration of 14 
phaeosphaeride A 19 (Figure 2), altering the originally proposed structure 53 through the total synthesis of ent-15 
phaeosphaeride A 54.[57] During the synthesis, the three adjacent stereocenters were built via Sharpless asymmetric 16 
dihydroxylation and the dihydropyran ring was formed via a stereoselective intramolecular vinyl anion aldol 17 
reaction.[57] 18 
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 22 
2.2 ISOPRENOIDS  23 
Isoprenoids are very widespread in fungi and most of them that feature important antitumor activity derive from 24 
endophyte cultures. A large number of these compounds are of great interest because of their biological and chemical 25 
properties. Among these, taxol is undoubtetly the most representative of terpenes with antitumor activity. It is well 26 
known that many fungal species produce taxol. However, seeing as the main natural source of taxol is a plant, we have 27 
decided that a comprehensive discussion on taxol is out of the scope of this review. Therefore, we have chosen to 28 
17 
 
present the other most intriguing terpens that are characterized by significant anticancer activity and synthesised over 1 
the past ten years and have not yet been included in previous reviews, as is in line with the overall target of this 2 
overview. The chemical structures of the compounds described are shown in Figure 3.  3 
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 6 
2.2.1 Illudins and Acylfulvenes (55, 56) 7 
Illudins are a family of highly cytotoxic sesquiterpene secondary metabolites of basidiomycetes. Illudins S and M 8 
(55a and 55b Figure 3) are landmarks that belong to this class of compounds and were the first identified from the 9 
bioluminescent mushroom Omphalotus illudens, in the 1950s [59], and the most cytotoxic members of the family. 10 
Acylfulvenes (56 Figure 3) are semisynthetic derivatives of illudins that were obtained in the course of developing 11 
cytotoxic agents with improved therapeutic properties. Recent advances in the synthesis of both illudins and 12 
acylfulvenes are thoroughly described in Sturla and Tanasova’s review, published in 2012, regarding the chemistry and 13 
biology of acylfulvenes.[59] To the best of our knowledge, noteworthy progress has not been reported on the subject 14 
since then. We will therefore not discuss the synthetic aspects of these sesquiterpenes any further in this review.  15 
In 2014, Hawkins and co-workers disclosed the use of sterically controlled Diels–Alder cycloadditions of 16 
allylidenecyclopropane for provide access to the tricyclic core of illudins.[60] 17 
 18 
2.2.2 Merulin A (57) 19 
Merulin A (57 also named steperoxide B, Figure 3) is a sesquiterpenoid belonging to the very recently reported 20 
group of chamigrane/norchamigrane endoperoxides.[61] It was isolated from mangrove endophytic fungi Xylocarpus 21 
granatum [61a] and showed significant cytotoxic activity against human breast cancer and colon cancer cell lines.[61a] 22 
In 2015, Wu and Chen reported a synthetic study of several members of the chamigrane family, of which merulin A, 23 
which was obtained in racemic form, stands out.[62] Critical steps of the synthetic route are shown in Scheme 13 and 24 
feature: i) a novel facial selective epoxidation of (±)-norchamigrene 61 that leads to the subsequent and highly-unstable 25 
epoxide as a single diastereomer; ii) a clean rearrangement of the epoxide to allylol 62; iii) a Co(II)-mediated 26 
silylperoxidation which provides the pivotal peroxy bridge-containing ring system 63 of the chamigrane endoperoxide 27 
family for the first time; iv) a carefully controlled reduction of 64 to yield racemic 57. The absence of any heteroatoms 28 
or additional stereogenic centers in the spirocyclic diene 61 to differentiate the two faces of the reacting C−C double 29 
18 
 
bond in the epoxidation and the optimal results observed with HCl/MeOH (among cheapest reagents available) in the 1 
subsequent rearrangement are quite remarkable. The key intermediate 61 was prepared via a nine-step sequence starting 2 
from methyl geranate in a 31% overall yield. In the same work, Wu and Chen carried out the adaptation of the 3 
diastereoselective synthesis to an enantioselective one via optically active (R)-61, which was obtained with a slight 4 
modification to Stoltz’s method.[62]  5 
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  9 
2.2.3 Aphidicolin (58) 10 
Aphidicolin (58 Figure 3) is a tetracyclic diterpenoid metabolite produced by various fungi, including 11 
Cephalosporium aphidicola, N. sphaerica and Harziella entomophilla.[3] It reversibly inhibits DNA polymerases α and 12 
δ and therefore has been widely used as a synchronizing agent in experimental systems.[3] Owing to its poor water 13 
solubility, it is unsuitable for parenteral administration but its water-soluble analogue, aphidicolin glycinate, has 14 
undergone Phase I clinical trials as a synchronizing agent.[3] A complete review of the syntheses of aphidicolin was 15 
published by Toyata and Ihara in 1999.[63] A few further advances have been made in the field and have been quoted 16 
in a Banerjee et al. review which covers the period from 1999 to 2009.[64] In 2009, Little and Zhong described the 17 
application of an intramolecular diyl trapping cycloaddition reaction to construct the bicyclo [3.2.1] framework of an 18 
aphidicolin synthetic intermediate.[65] 19 
 20 
2.2.4 Formitellic Acid B (59) 21 
Formitellic acids produced in the mycelium of a basidiomycete Perenniporia  (Fomitella) fraxinea were originally 22 
isolated by Sakaguchi and co-workers.[66] In recent years, they have proven themselves to be potent inhibitors of DNA 23 
polymerase and DNA topoisomerases which have been recognized as important enzymatic targets for cancer 24 
chemotherapy.[66] Structurally, formitellic acids are triterpenoids which feature a highly oxygenated steroidal AB ring 25 
(Figure 3). Concerning the synthetic aspects of this class of compounds, only the asymmetric total synthesis of 26 
formitellic acid B (59 Figure 3) has been accomplished so far and was published by Kobayashi’s group in 2009.[67] 27 
The central point of the convergent synthesis (Scheme 14) was the coupling of the A/B ring aldehydic precursor 65 with 28 
the C/D bicyclic vinyl iodide 66. The authors coupled these two fragments via the 1,2-addition of the vinyl lithium 29 
species, derived from 66, to the aldehyde 65. The last two pivotal features were: i) the stereoselective synthesis of the 30 
tetracyclic intermediate 67 (all requisite chiral centers) via a titanium(III)-mediated radical cascade cyclization of  68; 31 
ii) the formation of the enone motif in the B-ring via the isomerization of the olefin, followed by allylic oxidation. 32 
19 
 
Intermediate 65 was prepared via a stereoselective vinylogous Mukaiyama aldol reaction and a Sharpless asymmetric 1 
epoxidation. On the other hand, fragment 66 was stereoselectively synthesized from the dione derived from the (−)-2 
Wieland–Miescher Ketone (WMK). Nevertheless, this synthetic route is very long and consists of a total of almost 30 3 
steps and gives a poor overall yield (4% from 67). 4 
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Scheme 14 Strategy for the first synthesis of formitellic acid B 59  7 
 8 
2.2.5 Wortmannin (60) 9 
Wortmannin (60 Figure 3) is a furanosteroid initially isolated from Penicillium wortmannii, and then afterwards 10 
also from Fusarium torulosum and Trichoderma sp.[3] It is one of the most potent naturally occurring PI3-kinase 11 
inhibitors, but is not selective and has shown highly toxicity which has made it difficult to evaluate its in vivo activity as 12 
an antitumor agent.[3, 68] Wortmannin derivative PX-866 is currently under clinical evaluation.[3] Two excellent 13 
reviews regarding the synthetic aspects of wortmannin and itd derivatives were published in 2005[68a] and 2013.[68b] 14 
To the best of our knowledge, no new updates have been made, meaning that we consider it redundant to present the 15 
syntheses of wortmannin herein. 16 
 17 
2.3 QUINONES 18 
Quinone derivative metabolites of fungal endophytes have been reported to inhibit tumor cell lines. We herein 19 
review the recent total syntheses of representative examples of these fungal metabolites that have occurred since 2000 20 
to date. They involve benzoquinone (namely torreyanic acid (69), tauranin (70)), naphthoquinone and anthraquinone 21 
derivatives (bikaverin (71), rubrofusarin B (72), halenaquinone (73)), anthraquinones (cytoskyrin A (74a), rugulosin 22 
(74b) and deoxybostrycin (75)), macrosporin (76), pachybasin (77), nidurufin (78a), averufin (78b), versicolorins (79) 23 
and topopyrones (80 and 81)). The structures of the compounds considered in this section are reported in Figure 4.  24 
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Figure 4 Structures of the discussed quinones 2 
 3 
2.3.1 Torreyanic Acid (69) 4 
Torreyanic acid (69 Figure 4) is a dimeric epoxybenzoquinone isolated from Pestalotiopsis microspore, which is 5 
present in Torreya taxifolia (a species related to the taxol-producing Taxus brevifolia). It showed cytotoxicity against 25 6 
human cancer cell lines and greater activity against cell lines sensitive to protein kinase C (PKC) agonists; it 7 
presumably causes cell death by apoptosis.[69]  8 
The first total synthesis of the heptacyclic structure of 69, which bears 12 oxygen atoms and 8 stereogenic centers, was 9 
reported by the group of Porco who obtained both racemic [70] and enantiomeric pure acids.[71] These biomimetic 10 
syntheses were based on a sequence of oxidation and electrocyclization steps, followed by a Diels-Alder 11 
heterodimerization of key intermediate monomers 82 (Figure 5).  12 
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 3 
Diastereomeric monomers were prepared, via a multi-step synthesis, from a 1,3-dioxane derivative 83 to the protected 4 
hydroquinone precursor 84. The thermal Claisen rearrangement converted the ortho-allylated phenol directly to the 5 
quinone monoacetal 85. Monoepoxidation and the attachment of the eptenyl side chain afforded the required racemic 6 
quinone epoxide 86.[70] The 2-methyl-2-butenoic acid side chain was then inserted via terminal olefin oxidation, two-7 
carbon homologation and Stille vinylation. After the removal of protecting groups, the required quinone epoxide was 8 
oxidised with Dess-Martin periodinane to monomers 82, which gave two dimeric products. These products, after ester 9 
removal, gave racemic torreyanic acid along with its stereoisomer iso-torreyanic acid (Scheme 15, A).  10 
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Scheme 15 Porco’s synthesis of torreyanic acid; A: a) i. BuLi, 3:1 hexane/benzene, -25 °C, 10 h; ii. BrCF2CF2Br, THF, 12 
0.5 h, 70%; (b) 13 M HCl, THF, 10 min, 100%; (c) H2SO4,70 °C, 14 h, 52%; (d) allyl bromide, K2CO3, DMF, 3 h; (e) 13 
NaBH4, EtOH, 0.5 h; (f) TBDPSCl, imidazole, DMF, 2.5 h (90% for three steps); (g) (i) neat, 180 °C, 2 h, (ii) 14 
PhI(OAc)2, MeOH, 20 min; 70%; (h) HO(CH2)3OH, PPTS, C6H6,80 °C, 20 min, 90%;(i) Ph3COOH, KHMDS, THF, -15 
78 to -20 °C, 6 h, 81%; (j) catalytic OsO4, NMO, acetone/H2O, 25 °C, 15 h; (k) Pb(OAc)4, THF, 15 min, 96%; (l) 16 
PPh3=C(CH3)COOtBu, DCM, −35 to −10 °C, 4 h, 64%; (m) (E)-tributyl-1-heptenyl stannane, Pd(PPh3)4, PhCH3, 110 17 
°C, 1.5 h, 97%; (n) TBAF/AcOH (1:1), THF, 18 h, 72%; (o) 48% HF, CH3CN, 15 min, 93%;(p) Dess-Martin 18 
periodinane, DCM, 1 h, SiO2, 80%; (q) TFA/DCM (25:75), 2 h, 100%.  19 
B: (a) NaIO4, OsO4, THF/H2O, 1.5 h, 62%; (b) BH3. tBuNH2, MeOH/H2O, THF, 0 °C, 20 min, 76%; (c) Ph3COOH, 20 
NaHMDS, L-DIPT, 4 Å MS, Tol,−40 °C, 50 h, 91%, 91% ee; (d) (i) Dess-Martin periodinane, DCM, 35 min; (ii) 21 
PPh3=C(CH3)COOtBu, DCM,−78 to −5°C, 4 h, 94%; (e) (E)-tributyl-1-heptenylstannane, Pd(PPh3)4, Tol, 110 °C, 2 h, 22 
94%; (f) TBAF/AcOH (1:1), THF, 20 h, 76%; (g) 48% aq HF, MeCN, 15 min, 93%. 23 
22 
 
 1 
They were produced by an endo-selective [4 + 2] Diels-Alder heterodimerization of monomers 82, which are epimeric 2 
at C9 (C9′). The pentyl chains are anti to one another in the [4 + 2] transition state with the dienophile approaching the 3 
diene anti to the epoxide moiety. The asymmetric total synthesis [71] was achieved from the above reported 4 
experimental findings. As expected enantiomeric pure torreyanic acid was synthesized using the non-racemic epoxide 5 
(+)-86. The enantioselective oxidation was achieved using a tartrate-mediated nucleophilic epoxidation, developed by 6 
the same research group. The reaction was carried out on the quinone monoketal 87, which was obtained from the 7 
modification of the allyl side chain (Scheme 15; B).   8 
A new total synthesis of (±)-torreyanic acid using a biomimetic approach was reported by Metha [72] in 2004 (Scheme 9 
16). The readily available allyl-substituted p-benzoquinone 88, where the allyl group serves as surrogate of the tiglic 10 
residue of the natural product, was converted into a norbornyl scaffold via a Diels-Alder reaction, from which the the 11 
stereo-, regio-  and chemoselective steps for the synthesis of the epoxyquinone derivative 89 were performed; the endo-12 
tricyclic scaffold dictated the exo-stereoselectivity. This intermediate was then converted into the required 13 
epoxyquinone monomer 90 using a multistep synthesis for the introduction of the tiglic residue and the alkenyl side 14 
chain; two steps required photochemical equilibration. Dess-Martin periodinane oxidation finally gave the dienal 91 15 
which give two diastereomeric 82 via a 6π electron cyclization in two disrotatory modes. These rapidly react as in 16 
Porco’s procedure to give (±)-torreyanic and “iso”torreyanic acid after ester group removal (Scheme 16). 17 
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Scheme 16 Metha’s synthesis; a) Cyclopentadiene, MeOH, 0° C, 98%; b) 10%Na2CO3, 30% H2O2, acetone, 0 °C, 92%; 19 
c) 35% formalin, DBU, THF, 0 °C, 30 min, 95%; d) TBSCl, imidazole, DMAP, DMF, o °C, 90%; e) 35% formalin, 20 
DBU, THF, rt, 36 h, 80%; f) NaBH4, MeOH, −5 °C, 84%; g) Et2O, 220 °C, 96%; h) TEMPO, O2, CuCl, DMF, 90%; i) 21 
i. Ac2O, Py, DMAPP, 98%; ii. n-C6H13PPh3Br, t-BuOK, THF, 0 °C, 65%;  j) OsO4, NMO, −20 °C, 45%;  k) hν, 450W 22 
(Hanovia), I2, CDCl3, 80%; l) Pd(OAc)4, THF, 0 °C, 95%; m) Ph3P=C(Me)CO2tBu, −78 to −5°C, 55%;  n) i. LiOH, 23 
MeOH, −5 °C, 65%; ii. TPAP, NMO, mol sieve 4 Å, 85%,(o) HF, Py, 0 °C, 90%; p) Dess-Martin periodinane, DCM; q) 24 
Silica gel, 75% overall; r) TFA, DCM, 100%.  25 
 26 
2.3.2 Tauranin (70) 27 
The sesquiterpene quinone (-)-tauranin (70 Figure 4) has been isolated from the mold Oospora aurantia and fungus 28 
Phyllosticta spinarum, an endophytic strain of Platycladus orientalis. It has displayed in vitro antiproliferative activity 29 
against five sentinel cancer cell lines.[73] The total synthesis of (-)-tauranin was reported in 2009 [74], and was enabled 30 
by a lipase-catalyzed optical resolution of racemic albicanol (>99% ee), which was developed by the same authors. The 31 
Dess–Martin oxidation of (8aS)-albicanol (92, 99% ee) gave (8aS)-albicanal (93). Its reaction with an anion, generated 32 
from the required aromatic building block, afforded a diastereomeric mixture of (8aS)-94. The diastereomeric mixture 33 
was converted into (8aS)-95. The deprotection of the methoxymethyl (MOM) group was then investigated and it was 34 
found that this step is governed by the concentration of the camphor sulfonic acid used in EtOH. Finally, oxidation by 35 
Fremy’s salt gave (8aS)-70 (six steps, 31% overall yield) (Scheme 17).  36 
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Scheme 17 a) DessMartin periodinane, NaHCO3, 94%; b) n-BuLi, 91%; c) NaHDMS, CS2, MeI, AlBN, Bu3SnH, 76%; 2 
d) CSA, EtOH, 70%; e) (KSO3)2NO, phosphate buffer, 63%. 3 
 4 
2.3.3 Bikaverin (71) 5 
Naphthoquinone bikaverin (71 Figure 4) is a red pigment that was first obtained from Gibberella fujikuroi and then 6 
from Fusarium oxysporum EPH2RAA in Ephedra fasciculate and Cylindropuntia echinocarpus.[75] This polyketide 7 
showed selective cytoxicity against four sentinel cancer cell lines and has been compared to the standard compound 8 
doxorubicin.[75b]  9 
The most recent syntheses of bikaverin were reported in 1992 and 1993. In the first procedure, the non-catalyzed 10 
thermal condensation of the Mannich base 96 with 3-methoxy-5-methylphenol and subsequent dehydration gave o-11 
quinonic chromene 97. Isomerization, oxidation and selective dealkylation followed to give bikaverin in a six-step route 12 
(Scheme 18).[76] 13 
 14 
OMe
OMe
OMeHO
O
O
OMe
OMe
OMeHO
O
O
N
OMe
OMe
MeO
O
O
O
Me
MeO
96 97
71
a b-c d-f
 15 
Scheme 18 a) piperidine, CH2O; b) 3-methoxy-5-methylphenol, toluene, reflux, 1 h, 40%; c) anhydrous AcOH, 110 °C, 16 
10 min, 100%; d) Toluene, silica, AcOH, 80 °C; e) CrO3, AcOH, 2 min, 10 °C, 10%; f) LiI, DMF, yield not reported. 17 
 18 
The other synthesis was based on a key intermediate phenoxynaphthoquinone, which was subjected to intramolecular 19 
acylation, oxidation and dealkylation to regioselectively give bikaverin.[77] 20 
In previous syntheses, the benzo[b]xanthen-12-one scaffold was regiospecifically synthesized via the condensation of 21 
(phenylsulfony1)isobenzofuranones with chromones,[78] from the acylation of 1,2,4,5,8-pentamethoxynaphthalene and 22 
pyrolysis of the intermediate spyrocompound [79], from orcinol and 3-(2,4,5-trimethoxyphenyl)propiononitrile [80] and 23 
from everninic acid and 3,5-dihydroxybenzoic acid.[81] 24 
 25 
24 
 
2.3.4 Rubrofusarin B (72) 1 
The naphtha-γ-pyrone rubrofusarin B (72 Figure 4) (rubrofusarin monomethyl ether) was isolated from Aspergillus 2 
niger IFB-E003, an endophyte of Cynodon dactylon. It was found to be cytotoxic to colon cancer cell line SW1116 and 3 
also reversed the multidrug resistance of human epidermal KB carcinoma cells.[82] The first synthesis of rubrofusarin 4 
was reported by Shibata in 1963 and 1967, as starting from 2-acetylnaphthalene as the key intermediate [83]. The 5 
intermediate was reacted with ethyl acetate and then cyclized to give either rubrofusarin or its mono and dimethyl 6 
ethers. A biomimetic synthesis of rubrofusarin B from the orsellinate anion and pyrylium salt was reported in 1984. 7 
Although the reaction did not show selectivity, the major product was 2-benzyl-γ-pyrone, which was cyclized to 8 
rubrofusarin B using a base that does not open the pyrone ring.[84]  9 
 10 
2.3.5 Halenaquinone (73) 11 
Halenaquinone (73 Figure 4) was isolated from two Indo-Pacific collections of the sponge Xestospongia cf. 12 
carbonaria along with other metabolites, all featuring a pentacyclic polyketide skeleton.[85] These natural products 13 
were tested for their ability to act as inhibiting agents of various protein tyrosine kinases and halenaquinone was shown 14 
not to be a general kinase inhibitor.  15 
The first 15-step total synthesis of (+)-halenaquinone and (+)-halenaquinol (101) was reported in 1988, when the 16 
tetracyclic structure was obtained from a Diels-Alder reaction between the optically pure dienophile 98 and 99 to afford 17 
100.[86] (8aR)-(-)Wieland-Miescher Ketone was chosen as the starting material for 98 due to the absolute configuration 18 
of (+)-73 and (+)-(101) which had previously been theoretically determined. It was converted to enone (+)-(98) via a 19 
nine-step reaction, including selective protection steps, hydroxymethylation, reduction and oxidation reactions. This 20 
was reacted with 3,6-dimethoxybenzocyclobutene (99, obtained by a suitable sulfone pyrolysis). The furan ring was 21 
formed via the intramolecular cyclization of 100. The obtained halenaquinol dimethyl ether was finally converted into 22 
products 73 and 101 in a sequence of five total steps (Scheme 19, A). 23 
A catalytic asymmetric synthesis of (+)-(101) and (+)-(73) was reported by Shibasaki in 1998. The starting reagent was 24 
the commercially available 6,7-dimethoxy-1-tetralone (102).[87] The synthetic procedure was based on a cascade 25 
Suzuki cross-coupling/asymmetric Heck reaction/one-pot construction of the required pentacyclic framework from a 26 
tricyclic one, 103, which bears a benzylic quaternary carbon center. Compound 103 was obtained via three different 27 
syntheses with 85% ee. Compound 104 then was envisaged as an intermediate for a pentacyclic scaffold synthesis in a 28 
one-pot reaction. Therefore, 103 was converted into 104 via a multi-step sequence of reactions (including several steps 29 
of group protections). The final cyclization to the desired pentacycle was performed in a single step with a Heck 30 
reaction. After desilylation, the product was converted into halenaquinone and halenaquinol (Scheme 19, B). 31 
A short strategy for the synthesis of the furan-fused tetracyclic core of 73 was described and also explored in a model 32 
study by Nemoto.[88] The synthesis was based on an intramolecular [4+2] cycloaddition reaction of the o-33 
quinodimethane as the key step. A short similar synthesis of (±)-halenaquinone was reported in 2001 and used o-34 
benzoquinone monoketals.[89] A  concise asymmetric and highly convergent synthesis of (-)-halenaquinone was 35 
recently reported as featuring a diastereoselective Heck cyclization and an intramolecular inverse-electron-demand 36 
Diels-Alder reaction involving a vinyl quinone.[90]  37 
 38 
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Scheme 19  2 
A: Shibasaki’s synthesis: a) Benzene, 210-215 °C, 20 h, 33%; b) DDQ, benzene, 89%; c) tBuOK, tBuOH, 02, 90%; d) 3 
60% aqueous AcOH; e) DMSO, DCC, benzene, TFA, Pyr, 44%; f) CAN, aqueous  MeOH, 45%; g) aqueous Na2S204, 4 
acetone, 100%.  5 
B: Nemoto’s synthesis: a) five steps, 58% overall yield; b) i. TBSCl, Et3N, DCM, 0 °C, ii. Tf2O, Et3N, DCM, −78 °C to 6 
rt, (two steps, 85%); c) CH2=CHMgBr, PdCl2(dppf).DCM, Et2O, −78 °C to rt, 100%; d) alkylborane OTBDPS deriv., 7 
PdCl2(dppf).DCM, K2CO3, THF, 50 °C, 69%; e) 9-BBN, THF, 0 °C to rt, iodoallyl OTBDPS deriv., PdCl2(dppf), 8 
DCM, K3PO4, THF, 50 °C, 90%; f) i. Bu4NF, THF, 0°C; ii. Tf2O, Et3N, DCM, −78 °C to rt (two steps, 69%); g) 9 
Pd(OAc)2, (S)-BINAP, K2CO3, THF, 60 °C, 22h, 78%; h) five steps, 73% overall yield; i) DDQ, DCM-H2O, rt, 96%; j) 10 
O2, tBuOK, tBuOH, 35 °C, 79%; k) NaI, CuSO4, MeOH, H2O, rt, 97%; l) TsOH.H2O, acetone, H2O, 60 °C, 98%; m) 11 
Pd2(dba)3.CHCl3, K2CO3, DMF, rt, 72%; n) i. Bu4NF, AcOH, MeCN, THF, 60 °C, 83%; ii. CAN, MeCN, H2O, rt, 99%; 12 
o) Na2S2O4, acetone, H2O, 0 °C, 100%. 13 
 14 
2.3.6 Cytoskyrin A (74a) and Rugulosin (74b) 15 
Bisanthraquinone cytoskyrin A (74a Figure 4) and rugulosin (74b) were isolated from Cytospora sp. in Conocarpus 16 
erecta [91] and from Penicillium islandicum,[92]  respectively. Cytoskyrin exhibited potent DNA-damaging activity 17 
and inhibited four human carcinoma cell lines. Their synthesis were developed by Nicolaou in the course of model 18 
studies toward cytoskyrin A and 2,2'-epi-cytoskyrin A, although the latter is not a natural product. He discovered that 19 
all the bonding patterns found within the above compounds, and other related bisanthraquinones with varying degrees 20 
of oxidation and bonding joining, could be selectively formed in controlled one-pot cascade reactions starting from a 21 
monomeric anthraquinonic precursor unit.[93] The nonacyclic cytoskyrin model structure was prepared via a five-step 22 
cascade sequence involving the transformation of the tricyclic monomer 105 into the nonacyclic system 109 in 66% 23 
overall yield. The reaction sequence can be run one-pot or interrupted at each intermediate step.[93c] After initial 24 
enolization, stereoselective dimerization to 106 and oxidation to 107 by MnO2 (excess), an intramolecular double 25 
Michael sequence, in the presence of Et3N (10.0 equiv), afforded the cytoskyrin model scaffold 109 via the intermediate 26 
fleeting compounds 107 and 108 (Scheme 20). 27 
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Scheme 20 Nicolaou’s synthesis of the nonacyclic cytoskyrin model system 109: a) CSA, DCM; b) MnO2; c) Et3N; d) 2 
Et3N; e) Et3N; f) MnO2, Et3N; g) CSA, MnO2, Et3N.  3 
 4 
Nicolaou later reported the first biomimetic asymmetric total synthesis of (+)-2,2’-epi-cytoskyrin A using the 5 
“cytoskyrin cascade” described above. The model system differed from natural products in its lack of C2 and C2’ 6 
hydroxyl groups, whose presence could be problematic as aromatization favored their elimination in a total synthesis 7 
based on a dimerization of two monomeric units. Various monomeric units were prepared and studied after detailed 8 
investigations into the stereochemistry of monomeric anthraquinone dimerization and the nature of the hydroxy 9 
protecting groups at C2/C2’. Required fragments 110 and 111, prepared as reported,[93b] gave dihydroquinone 10 
derivatives 112 which, when subjected to the cascade sequence, led to the nonacyclic structure 113 (60% overall yield). 11 
(+)-2,2’-epi-cytoskyrin A (114) was obtained in a 93% yield after complete deprotection. The same reaction sequence 12 
afforded (+)-74b (50 % yield over seven steps and 98% after global deprotection) (Scheme 21).[93b, 93d] 13 
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Scheme 21 First biomimetic asymmetric total synthesis of (+)-2,2’-epi-cytoskyrin A: a) i. LHMDS, THF, 1 h, −78 °C; 1 
ii. enone, −78 °C, 1h, to rt; b) i. MnO2, DCM, 1h, 25 °C; ii. Et3N, DCM, 25 to 45 °C, 12h; c) HCl conc., MeOH, THF, 2 
60 °C, 12 h. 3 
 4 
2.3.7 Deoxybostrycin (75) 5 
The natural tetrahydroanthraquinone deoxybostrycin (75 Figure 4) was isolated from the mangrove endophytic 6 
fungus Nigrospora sp. No. 1403, from the South China Sea, which shows phytotoxic, antimalarial, antimycobacterial 7 
and cytotoxic activities.[94] An enantioselective synthesis of (+)-bostrycin was reported as occurring via an asymmetric 8 
Diels-Alder reaction, which involved a protected naphthopurpurin and a D-glucose-derived diene.[95] New derivatives 9 
were synthesized and their in vitro cytotoxicity was tested against three cancer cell lines; most of the compounds 10 
exhibited strong cytotoxicity.[96] 11 
 12 
2.3.8 Macrosporin (76)   13 
The anthracenone macrosporin (76 Figure 4) was initially isolated from acrosporium porri [97] and then from 14 
Alternaria solani, Dactylaria lutea, Stemphylium eturmiunum, Alternaria tomatophilia, Ampelomyces sp., an 15 
undetermined fungicolous hyphomycete resembling Cladosporium and Stemphylium globuliferum. (it is not clear which 16 
of the previous fungi this last description refers to) Macrosporin displays moderate cytotoxic activity in L5178Y mouse 17 
lymphoma cells.[98] 18 
After the first total synthesis of macrosporin, via the Diels–Alder reaction of a 1,4-naphthoquinone and a diene,[99] a 19 
new biomimetic seven-step synthesis has recently been reported as occurring via the initial preparation of 6-20 
benzylresorcylate 115 and its subsequent conversion to anthrone 116 by cyclization and final oxidation to macrosporin 21 
(Scheme 22).[100] 22 
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Scheme 22 Total synthesis of macrosporin: a) H2, Pd/C, EtOAc, 20 °C, 18 h, 95%; b) TMSOTf, DCM, 20 °C, 18 h, 24 
76%; c) O2, CuBr2, THF, 20 °C, 20 h, 81%. 25 
 26 
2.3.9 Pachybasin (77), Nidurufin (78a) and Averufin (78b) 27 
Many anthracenedione derivatives which show anticancer effects to some extent have been isolated from fungal 28 
species. The list includes pachybasin (77 Figure 4), from mangrove endophytic strains of Guignardia sp. and 29 
Halorosellinia sp. and nidurufin, from a spongiculous strain of Aspergillus versicolor, versicolorin A and B, as well as 30 
8-O-methyl- and 6,8-O-dimethylaverufin, produced by a strain of Penicillium flavidorsum (syn. P. glabrum) recovered 31 
28 
 
from marine sediments.[1] These compounds are characterized by the presence of a variously oxidized side chain and, 1 
in particular, nidurufin and averufin are structurally closely related to 1,3,6,8-tetrahydroxyanthraquinones. 2 
The most recent pachybasin synthesis was reported in 1994, along with that of emodin and other naturally occurring 3 
hydroxyl-substituted anthraquinones. These compounds were obtained in high yields via the Diels-Alder reaction of 4 
naphthoquinones with substituted butadienyl silyl ketene acetals.[101] 5 
The first synthesis of racemic averufin was accomplished by Brassard via the hydroxyalkylation of 1,3,6,8-6 
tetrahydroxyanthraquinone with 5-oxohexanal at −85°C. Under these conditions, a 6.6% yield of product was 7 
isolated.[102] An improved synthesis of 1,3,6,8-tetrahydroxyanthraquinone was reported later. The Diels-Alder reaction 8 
in the Brassard synthesis was simplified and the quinone 117 was synthesized on a multigram scale and in a 50% 9 
yield.[103] It was then used as a reagent in a new total syntheses of the racemic forms of both averufin and nidurufin 10 
(20% and 24% overall yields, respectively (Scheme 23, A). In the modified averufin synthesis, described by Townsend, 11 
the key step involved the regiospecific coupling of the phthalide anion of 119 and the benzyne derived in situ from aryl 12 
bromide 120. The single isomer anthraquinone precursor of (±)-averufin was obtained thanks to the (methoxymethyl) 13 
protecting groups for regiospecific aryl metalation and the subsequent introduction of the electrophile.[104] Averufin 14 
was obtained in an 8% overall yield from ester 118 (Scheme 23, B). 15 
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Scheme 23 Averufin and nidurufin syntheses  17 
A: (a) i. PhSeCl, CCl4, 0 °C; ii.H2O, Pyr, tBuAA, NaH, DMSO, rt; (b) AcOH/H2O (1:1), cat. H2SO4; (c) p-TosOH 18 
Toluene, 90 °C, 50% two-steps yield; (d) m-CPBA, DCM, rt;  ; (e) AcOH/H2O (1:1), cat. H2SO4.  19 
B: (a) LiTMP, THF, −60 to −40 °C, 35%;  (b) aq  MeCOOH, H2SO4 traces, 85 °C under N2, 80%. 20 
 21 
A formal synthesis of (+)-averufin has recently been reported by Tan and Qiu as occurring in a biosynthetic mimic 22 
sequence catalyzed by proline and based on a Knoevenagel condensation and a [4+2] cycloaddition.[105]  23 
 24 
2.3.10 Versicolorins A (79a) and B (79b) 25 
Versicolorins A and B (79 Figure 4) are key precursors in Aflatoxin B1 and B2 biosynthesis, which are naturally 26 
occurring mycotoxins produced by Aspergillus flavus, A. parasiticus and A. nomius, and are among the most potent 27 
carcinogens known. In the course of the elucidation of aflatoxin B1 biosynthesis [106], Townsend reported the total 28 
syntheses of (±)-versicolorin B and (±)-versicolorin A along with other derivatives.[106b] the synthetic strategy 29 
involved two silyl triflate-mediated cyclization and rearrangement procedures that allowed both furofuran oxidation 30 
states to be produced while avoiding undesired, but thermodynamically favorable, side reactions. In the first procedure, 31 
29 
 
o-methoxymethylphenylacetaldehyde was cyclized to a five-membered hemiacetal. In the second, this same group, once 1 
properly substituted, rearranged to a 4-trialkylsilyloxy-2,5-methano-1,3-benzodioxepane. The sufficient stability of the 2 
latter masked the dialdehyde and allowed the construction of the desired aryl ring systems to occur.   3 
 4 
2.3.11 Topopyrones (80, 81) 5 
Topopyrones A, B, C and D (80, 81 Figure 4) are anthraquinones isolated from cultures of two unidentified strains 6 
(Phoma sp. and Penicillium sp.) [107], whose cytotoxicity is due to the inhibition of topoisomerases. Linearly fused 7 
Topopyrones B and D are especially potent and the activity of 81a against topo-I being is comparable to that of 8 
camptothecin. A number of research groups embarked upon their total synthesis. Ciuffolini’s research focused on linear 9 
compounds.[108] The cyclization of a suitable precursor under equilibrating conditions should only afford linear 10 
compounds on the grounds that alkali exposure causes the rearrangement of angular topopyrones A and C to linearly 11 
fused B and D (thermodynamically favored) [107]. The anthraquinone core was assembled in a single step via the 12 
reaction of 123 with aldehyde 122, which carried the features common to all topopyrones. Aldehyde 138 was prepared 13 
as described in Scheme 24: an organolithium species was added to aldehyde 121. The straightforward manipulation of 14 
the alcohol intermediate gave 122. The directed metalation of benzamide 123 then gave a Snieckus-type anion, which 15 
by reaction with aldehyde 122, formed the presumed intermediate 124. Treatment in situ with additional t-BuLi 16 
presumably induced bromine-lithium exchange, thereby triggering cyclization to the corresponding 17 
dihydroanthraquinone. Exposure to air finally afforded 126 (17 and 20% yield, R= H and R=Cl), in the one pot three-18 
step syntheses (after purification); corresponding debrominated compounds 125 were however the major products (60-19 
70%). The conversion of 126 to topopyrones D and B was achieved after desilylation, IBX oxidation and final exposure 20 
to 48% aqueous HBr solution (Scheme 24).  21 
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Scheme 24 Ciuffolini’s synthesis of Topopyrones D and B: a) t-BuLi, -78 °C, THF, then 121, 67%; b) i. TIPS-OTf, 23 
imidazole; ii. NBS, MeCN, 94%; c) i. TBAB; ii. Swern oxidation 81%; d) RLi, TMEDA, THF, −78 °C, then 122; e) t-24 
BuLi, −78 °C; f) i. TBAF, THF; ii. IBX, MeCN, reflux; g) 48% aq HBr, AcOH.   25 
The first total synthesis of topopyrone C and analogues was reported by Dallavalle[109]. The synthetic procedure 26 
entailed Marschalk alkylation of 1-hydroxy-3,6,8-trimethoxyanthraquinone 129, Baker–Venkataraman chain elongation 27 
and acid-catalyzed cyclization. Quinone 129 was obtained using two successive Diels–Alder cycloadditions between an 28 
excess of Brassard diene 127 and 2,6-dichloro-1,4-benzoquinone to obtain a mixture of 129 and 128 after pyrolysis. The 29 
mixture was then converted into 129, using methyl p-toluenesulfonate with an overall yield of 40% (Scheme 25).  30 
30 
 
OMe
OMe OSiMe3 +
Cl
O
Cl
O127
O
O
OH
MeO
OH
OMe
O
O
OMe
MeO
OH
OMe
+  129
128 129
a b
c,d
O
O
OMe
MeO
OH
OMe
O
e,f g
O
O
OMe
MeO
OH
OMe
O O O
O
OMe
MeO OMe
O
O h 80b
 1 
Scheme 25 Dallavalle’s synthesis of Topopyrone C: a) i. THF, -78 °C; ii. 130 °C, 10 h; iii. MeOH/HCl 10% 3:1 reflux, 2 
30 min; b) TsOMe, Na2CO3, tetraglyme, 140 °C, 2 h, 40%; c) i. NaOH, Na2S2O4, MeOH, 0 °C; ii. MeCHO, 20 °C, 3 h; 3 
iii. H2O2,0 °C, 30%; d) PCC, H5IO6, MeCN, 0 °C, 30 min, then rt, 3 h, 60%; e) Ac2O, Py, reflux, 10 h, 88%; f) LiH, 4 
THF, reflux, 20 h, 55%; g) CF3COOH, 0 °C, 20 min, rt, 10 min, 76%; h) BBr3, DCM, -60 °C, 90 min, 25%. 5 
 6 
A different strategy was adopted by Hecht for the synthesis of all four natural topopyrones and analogues.[110] The 7 
multistep synthesis included a titanium-mediated ortho-directed Friedel-Crafts acylation (to give 130) and Diels-Alder 8 
reactions using the novel diene 131. Topopyrones C and D were synthesized as reported in Scheme 26. Chlorinated 9 
topopyrones A and B were synthesized in a similar fashion (80a and 81a Figure 4). 10 
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Scheme 26 Hecht’s strategy for Topopyrone synthesis: a) i. NaH, EtOAc, reflux; ii. TFA, 84% two steps; b) CAN, 12 
MeCN, 96%; c) benzene, 70 °C, 54%; d) i. TBAF, THF; ii. BBr3, DCM, 65% two steps; e) 1% NaOH in MeOH, 70 °C, 13 
3 days, 57%. 14 
 15 
 16 
2.4 CHROMANOIDS   17 
Flavonoids are a class of polyphenolic compounds that are widely distributed in the plant kingdom as are their 18 
endophytes. Of the flavonoids produced by endophytic fungi, xanthones and chromones display antitumor activity. 19 
Xanthones are simple tricyclic ring compounds that are structurally related to anthraquinones and characterized by the 20 
inclusion of a γ-pyrone nucleus. The dimeric class of ergochromes, whose structure is based on two xanthene monomers 21 
linked at positions 2,2’, includes ergoflavin and secalonic acids. Isoprenylated chromone derivatives are also interesting 22 
and include pestaloficiol J. The structures of flavonoids considered in this review are reported in Figure 6. 23 
 24 
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Figure 6 Chemical structures of the discussed chromanoids 2 
 3 
2.4.1 Secalonic Acid D (132) 4 
Secalonic acid D (132 Figure 6) was isolated from Penicillium oxalicum in 1970 and was then found in other fungal 5 
species [111], and isolated from the mangrove endophytic fungus no. ZSU44. It was found to be extremely toxic and 6 
teratogenic, but also potently cytotoxic to human leukemia cells via the induction of apoptosis and the inhibition of 7 
DNA topoisomerase I. Its enantiomer, secalonic acid A, has shown significant cytotoxicity to several human cancer cell 8 
lines, such as HepG2, A549, Ca Ski, CNE2, MDA-MB-231 (liver cancer, adenocarcinomic, cervical cancer, 9 
nasopharyngeal carcinoma and breast cancer cell lines, respectively) [112], while its diastereomer secalonic acid B has 10 
antitumor activity.[113] The secalonic acids and other ergochromes have been the subject of hundreds of studies that 11 
have focused on both their fascinating structural features and biological activity.  12 
The first total synthesis of secalonic acids D and A, recently reported by Porco, can be regarded as a milestone in the 13 
synthesis of dimeric natural products, as the monomeric units are chiral.[113]  14 
The synthetic strategy entailed the preparation of a hemisecalonic derivative (monomeric natural tetrahydroxanthenones 15 
such as blennolide A) [114] and then its conversion to the corresponding iodide and stannane.[113, 115] Racemic 16 
blennolide 134 (synthesized via the vinylogous addition of siloxyfurans to benzopyryliums and then a Dieckmann 17 
cyclization in a maximum of four steps from a 5-hydroxychromone substrate) gave a blennolide derivative via methyl 18 
enol ether protection and ortho-iodination. Acylative kinetic resolution then provided both (+)-135 and (-)-136 in high 19 
yields and enantioselectivity (over 99% ee). MOM protection and then stannane formation gave the enantio-enriched 20 
tetrahydroxanthone (-)-137. Copper-mediated oxidative coupling gave a single dimeric product (+)-138. Overall 21 
deprotection with HCl provided 132 in a 81% yield (Scheme 27). This procedure achieved a significant synthetic goal, 22 
because, as was previously shown, the peculiar electronic nature of the monomeric xanthone framework was not 23 
suitable for more direct oxidation reactions. Since the iodide precursor can be pre-activated with trialkyl stannane at the 24 
ortho-position, the dimerization is thus reliably regioselective.  In a similar way, (-)-136 was converted into secalonic 25 
acid A, the enantiomer of secalonic acid D. After MOM protection and stannane synthesis, the intermediate 26 
tetrahydroxanthone was obtained (41% yield, two steps). Oxidative coupling led to the dimer (60%yield). Final 27 
deprotection with HCl gave secalonic acid A (85% yield). 28 
Since secalonic acids C, F, and G, as well as some of the other ergochromes and ergoflavins consist of two 29 
nonequivalent monomers, they cannot be prepared via the above synthetic method. The total synthesis of secalonic acid 30 
E was reported by Tietze.[116] The 2,4′-and 4,4′-linked variants of the cytotoxic agent secalonic acid A and their 31 
analogues have also been synthesized by Porco.[117] 32 
 33 
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Scheme 27 Secalonic acid D synthesis: a) MOMCl, DIEA, DMAP, DCM, rt, 12h, 81%; b) [Pd2(dba)3], PtBu3, Bu4NI, 2 
(SnBu3)2, 1,4-dioxane, 50 °C, 4 h, 56%; c) CuCl, DMA, air, rt, 60%; d) 3M HCl/acetone, 60 °C, 20 h, 81%. 3 
 4 
2.4.2 Pestaloficiol J (133) 5 
Isoprenylated chromone derivatives (pestaloficiol I, pestaloficiol J, pestaloficiol K and heterodimer pestaloficiol L), 6 
were isolated from Pestalotiopsis fici, a fungal endophyte of Camellia sinensis. They showed activity against HeLa cells 7 
and MCF7 cells, while pestaloficiol J (133 Figure 6) also displays moderate inhibitory activity against HIV-1 cells. 8 
Only 133 has been synthesized. In 2015, it was prepared via a microwave promoted tandem Claisen rearrangement and 9 
6-endo-dig cyclization sequence, with an overall six step yield of 38% (Scheme 28).[118]  10 
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Scheme 28 Synthesis of Pestaloficiol J: a) Pd(PPh3)4, THF, 0 °C, quant.; b) Me2C=CHMgBr, THF, 0 °C, 80%; c) 12 
(NPr4)RuO4, NMO, 4 Ǻ–MS, 66%; d) PhNEt2, MW (250 °C), 1h, quant; e) TBAF, THF, 0 °C, 93%. 13 
 14 
 15 
2.5 LACTONIZED KETIDES  16 
Lactones and esters are widespread fungal metabolites and anticancer activity has been reported in many of them. 17 
An overview of the discussed structures is reported in Figure 7. 18 
 19 
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Figure 7 Chemical structures of the discussed lactonized ketides  2 
 3 
2.5.1 Alternariol (139) 4 
The resorcylic lactones alternariol (139a Figure 7)[119] and alternariol 9-methyl ether (139b Figure 7) are the main 5 
metabolites of Alternaria fungi. Many syntheses of alternariol have been reported. In 2005, Podlech et al. reported the 6 
total synthesis of alternariol in seven steps from orcinol and 3,5-dimethoxybromobenzene. The key reaction is a 7 
palladium-catalyzed Suzuki-type coupling of an orcinol-derived boronic acid with a brominated resorcylic aldehyde 8 
(Scheme 29). The final lactonization and demethylation steps furnished alternariol in a 73% yield.[120] 9 
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Scheme 29 Strategy for alternariol synthesis 12 
 13 
A synthetic approach, based on a Pd catatlyzed Suzuki cross coupling, has more recently been proposed in two different 14 
papers.[121] Abe and coworkers [121b] reported the synthesis of alternariol via an intramolecular biaryl coupling 15 
reaction of the phenyl benzoate derivative and benzoic acid using a palladium reagent. The study of the regioselectivity 16 
of the biaryl coupling reaction was also investigated. 17 
 18 
2.5.2 Brefeldins (140) 19 
Brefeldin A (BFA, 140a Figure 7) was first isolated from Penicillium decumbens in 1958 [122] and subsequently 20 
from many others strains. Although many other names were once given to this compound, brefeldin A has gradually 21 
become the only one in use since the 1980s. BFA was shown to possess antifugal, antiviral, antitumor and nematocidal 22 
activity since the very earliest reports. Later on in the late 1990s, anticancer activity, including that of suppressing 23 
prostatic carcinoma LNCaP cells, was reported. Besides its antitumor effects, BFA has become an important tool for 24 
cell biologists as a result of its dramatic effects on the structure and functioning of intracellular organelles, particularly 25 
34 
 
the Golgi apparatus, and its remarkable ability to inhibit vesicle formation in mammalian cells.[119] Since the first total 1 
synthesis of (racemic) BFA by Corey and Wollenberg [123], around 30 total/formal syntheses have been reported in the 2 
literature.[124] Interest in probing modes of action and establishing structure-activity relationships has also obviously 3 
grown in recent years. Herein, we wish to provide an update of recent developments in the total enantioselective 4 
synthesis of brefeldin A. For the syntheses of brefeldin A, its derivatives and analogues published before 2008 see 5 
references in Wu et al. (2008).[124] These authors reported the total synthesis of 140a using a multistep approach 6 
which features: a) the construction of the five-membered ring from a Crimmins aldol via tandem Li−I exchange and 7 
carbanion-mediated cyclization with the concurrent removal of the chiral auxiliary; b) the introduction of the lower side 8 
chain (C10 to C16) via the Rh-catalyzed Michael addition of a vinyl boronic acid; c) the stereoselective reduction of the 9 
C7 ketone with SmI2; d) a 2-methyl-6-nitrobenzoic anhydride-mediated lactonization (Scheme 30). 10 
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Scheme 30 Total synthesis of Brefeldin A: a) t-BuLi/Et2O/-78 °C (75%). b) RhCl(COD)2 0.03 equiv MeOH.H2O, LiOH 12 
(95%), c) SmI2, THF (89%); d) MNBA (2-methyl-6-nitrobenzoic anhydride, DMAP (81%). 13 
The large majority of the synthetic approaches to brefeldins and its analogues are based on the creation of the C9–C10 14 
or C10–C11 bonds  and the C2–C3 or C3–C4 bonds, to create the larger ring of the molecule, which is followed by a 15 
final lactonization step. In contrast with these syntheses, Guingant and colleagues proposed an approach featuring the 16 
construction of three main fragments, resulting from the sequential disconnection of the C1–O σ bond, as well as the 17 
C11–C12 and C3–C4 σ bonds of the macrocyclic lactone , as outlined in Scheme 31.[125] 18 
O
O
H
H
OH
R1
R2
4
5
7
15
140
11
12
R1
O
O
I
H
H
fragment
 
1
(R1
 = H,
 
OPg)
OAc H O
O
Meor
fragment
 
3
B
OPMB
R2
H
fragment
 
2
(R2
 = Me,
 
H)  19 
Scheme 31 Total synthesis of Brefeldin C: retrosynthetic approach based on sequential disconnection of the C1–O σ 20 
bond as well as the C11–C12 and C3–C4 σ bonds. 21 
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According to this approach, the total synthesis of (+)-brefeldin C was accomplished in 15 steps in a 4.6% overall yield. 1 
In 2011, Tsunoda[126] and coworkers reported the total synthesis of (+)-brefeldin C which used an aza-Claisen 2 
rearrangement as the key step. As described in Scheme 32, the precursor was treated with LHMDS (2.5 equiv) at –78 3 
°C and then heated at 65 °C for 36 hours to give the rearranged amide [127] SR as the major product along with (RS). 4 
The diastereomeric mixture of amides was treated with TBAF in THF to give a separable mixture of OH amides, whose 5 
ratio was determined, by HPLC analysis, to be 85:15. After separation by SiO2 column chromatography, the pure amide 6 
SR was converted to lactone by the hydroboration of the exo-olefin with catecholborane, followed by acidic cyclization 7 
with p-toluenesulfonic acid. Further elaboration led to brefeldin C. 8 
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Scheme 32 Tsunoda’s synthesis of brefeldin C: a) i. LiHMDS (2.5 eq.), toluene, -78 °C. ii. 65 °C, 36 h; b) i. separation, 11 
ii. catecholborane, H2O2, NaOH, THF (85%); c) TsOH, toluene, 80 °C (89%). 12 
 13 
Even more recently, Fuchs and Fuerstner proposed an innovative approach to the establishment of the E stereochemistry 14 
of the macrolactone of brefeldin A and C.[128] Ring-Closing olefin Metathesis (RCM) at the C10-11 bond is the only 15 
catalytic method used to synthesize the macrocycle to date.[129] Unfortunately, the reaction is poorly stereoselective 16 
and, as a consequence, the observed isomer ratios were case dependent and typically unfavorable. The procedure for 17 
direct alkyne trans-hydrogenation proposed by Fuestner et al. (Scheme 33) consists of a ruthenium-catalyzed trans-18 
hydrogenation that is selective for the triple bond (the transannular alkene and the lactone site of the cycloalkyne 19 
precursors are not compromised). (please check meaning) 20 
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 24 
Scheme 33 Fuestner’s synthesis of brefeldin A: a) molybdenum alkylidyne complex catalyst (5 mol %), toluene, MS 5 , 25 
80 °C (67 %, 1.25 g scale); b) H2 (30 atm), [CpRu(MeCN)3]PF6, DCM (56%, 1.15 g scale); c) HCl aq, THF (94%).  26 
 27 
Cycloalkynes were used as the substrate for the crucial trans-hydrogenation. [CpRu(cod)Cl] was identified as a good 28 
catalyst for this transformation and furnished the product with excellent selectivity (E:Z>99:1). The equally reducible 29 
enoate moiety was not touched to any noticeable extent nor was the lactone cleaved by the Lewis-acidic catalyst species 30 
36 
 
that was generated in situ. Standard deprotection then furnished 163a as a colorless crystalline material, as confirmed by 1 
X-ray diffraction. 2 
 3 
2.5.3 Graphislactones (141) 4 
Graphislactones are a family of natural compounds whose basic framework consists of 6H-dibenzo[b,d]pyran-6-5 
one. Graphislactone A (141a Figure 7) was first isolated as a natural product from the lichen Graphis scripta var. 6 
pulverulenta in the late 1990s. Graphislacton H (141c Figure 7) has been isolated from the endophytic fungus 7 
Cephalos- porium acemonium IFB-E007. The biosynthesis of graphislactones is strongly related to that of Alternaria 8 
metabolites. In fact, as depicted in Figure 7, their structures are very similar and 3-desmethylgraphislactone A has been 9 
identified in the metabolism of Alternaria toxins. A number of different types of biological activity have been reported 10 
for graphislactones and related compounds. Graphislactone A is an antioxidant and a scavenger of free radicals, while 11 
graphislactones A, G and H have been found to be active against the SW1116 cell line, and graphislactone A and 12 
botrallin are moderate inhibitors of AChE.[130] In 2009, Podlech et al. [130b] proposed the synthesis of some members 13 
of the family of graphislactones, including graphislactone A and H (Scheme 34). The synthetic approach is based on a 14 
Suzuki coupling between two previously synthesized fragments. 15 
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Scheme 34 Syntheses of Graphislactone A and H: a) Pd(Ph3)4, Cs2CO3 (83%); b) BCl3 (39%); c) CH2N2 (quant). 17 
The total synthesis of graphislactone A was thus be completed in 10 steps and in a 16% yield. The synthesis of 18 
graphislactone H was achieved for the first time via the methylation of graphislactone A with diazomethane in a 19 
quantitative yield. The total synthesis was completed in 11 steps and a 16% yield. A similar approach was used by the 20 
same group to synthesize graphislactone G, a chlorinated resorcylic lactone.[131]  21 
 22 
2.5.4 Sch 642305 (142) 23 
Towards the end of 2003, the isolation and structure elucidation of a novel natural product, Sch 642305 (142 Figure 24 
7), which was isolated from the fermentation broth of the fungus Penicillium verrucosum (culture ILF-16214), has been 25 
reported.[132] Compound 142 exhibited inhibitory activity against the Escherichia coli bacterial DNA primase enzyme. 26 
It should also be pointed out that very few natural products exhibiting DnaG inhibition activity have been reported so 27 
far. Furthermore, a more recent report indicates that Sch 642305, isolated this time from the fungus Septofusidium sp., 28 
exhibits inhibition of HIV-1 Tat-dependent transactivation.[133] HIV-1 Tat is essential for viral replication, making the 29 
Tat-protein is a challenging  target for the development of new therapeutics for the treatment of HIV infection.[133] 30 
From a purely structural perspective, Sch 642305 consists of a decalactone moiety fused to a 4-hydroxycyclo-hexenone 31 
ring. The additional presence of four stereogenic centers makes it a challenging and attractive synthetic goal. One of the 32 
most recent syntheses found in the literature, the report by Metha et al. [134] of the enantioselective total synthesis of 33 
Sch 642305 is based on a RCM protocol to construct the key decalactone moiety (Scheme 35). 34 
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Scheme 35 Metha’s synthesis of Sch 642305: a) Grubbs II catalyst (10 mol%), DCM, reflux, 2 h, 84%; b) 4 
PdCl2(CH3CN)2, moist acetone, rt, 5 h, 94%; c) Dess–Martin periodinane, DCM, 0 °C, 6 h, 95%; d) 10% Pd/C, H2, 5 
EtOAc, 96%; e) LHMDS, PhSeCl, THF, 278 °C; f) H2O2, pyridine, DCM, 0 °C, 10 min (78% two steps); g) TBAF–6 
AcOH (1 : 1), THF, RT, 8 h, 91%. 7 
 8 
The substrate was exposed to the second generation Grubbs catalyst and which enabled the bicyclic framework to be 9 
formed, embedding the decalactone moiety. Further synthetic elaboration, as described in Scheme 41, furnished the 10 
target molecule (+)-142. The synthetic compound was found to be spectroscopically identical to the natural product. A 11 
complementary synthesis, in which the formation of the macrolide is based on a lactonization process, has been 12 
proposed by Watanabe et al. (Scheme 36).[135] The stereoselective synthesis of Sch 642305 started from a chiral alkyl 13 
iodide obtained by chiral reduction using baker’s yeast and used to alkylate a b-ketosulfoxide via a dianion procedure. 14 
The product was obtained with the desired stereochemistry and was used as a substrate for the following Yamaguchi 15 
lactonization. The overall yield was 10% after 18 steps which started from the chiral building block. 16 
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Scheme 36 Watanable’s  stereoselective synthesis of Sch 642305: a) LDA, THF; b) CaCO3, toluene (47% in two steps); 19 
c) HF, CH3CN (98%); d) Dess–Martin periodinane, CH2Cl2 (84%); e) NaClO2, 2-methyl-2-butene, NaH2PO4.2H2O, 20 
tert-BuOH, water (90%); f) MgBr2.Et2O, ether (quant); g) 2,4,6-trichlorobenzoylchloride, NEt3, THF then DMAP, 21 
toluene (73%); h) TBAF, AcOH, THF (87%). 22 
 23 
It is worth mentioning that the synthesis of (+)-Sch 642305 was completed in 17 steps in a 1.6% overall yield by Snider 24 
et al. in 2006.[136] The transannular Michael reaction of the macrolactone represented in Scheme 37 with NaH in THF 25 
38 
 
provided cyclohexenone stereospecifically. The treatment of cyclohexanone, which was obtained in TFA/CDCl3, 1 
provided a 3:1 equilibrium mixture of diastereoisomers. Upon separation, the diastereoisomer of interest was 2 
hydrolyzed to give (+)-Sch 642305. 3 
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Scheme 37 Snider’s synthesis of Sch 642305: a) 1.2 eq. NaH, THF, 0 °C, 30 min; b) 1.5% TFA, CDCl3, 120 °C, 3h; c) 5 
TBAF, HOAc, THF. 6 
 7 
The most recent papers on the synthesis of Sch 642305 appeared in 2007. Kita et al. proposed the enantioselective 8 
synthesis of (+)-Sch 642305.  The chiral non-racemic hydrobenzoin was used as a chiral auxiliary for multiple 9 
purposes: a) the desymmetrization of the diene, b) a template for attaining regio- and stereoselective reactions, c) as an 10 
oxygen source at the C4-position, and d) as a protecting group for the hydroxyl functions. In particular, the chiral 11 
auxiliary played a role in every step throughout the synthesis.[137] In the same year, Trauner et al. proposed a highly 12 
convergent, enantioselective synthesis of (+)-Sch 642305 which featured a Mukaiyama−Michael addition followed by 13 
allylation to establish the syn−anti relationship of the three contiguous stereocenters.[138] As shown previously, the 10-14 
membered macrolactone was instead formed via ring-closing metathesis (Scheme 38).[134] 15 
 16 
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Scheme 38  Trauner’s enantioselective synthesis of Sch 642305: a) TASF (56%); b) Grubbs II (63%); c) H2, Pd-C 19 
(96%); d) NaHMDS, TESCl, Pd(OAc)2 (61%); e) TBAF-AcOH (73%). 20 
 21 
Starting silyl enol ether was subjected to stereoselective allylation with allyl bromide in the presence of TASF, giving 22 
cyclohexanone 145 in good yield and with excellent diastereoselectivity. This was then used as a substrate for a RCM 23 
reaction with a second generation Grubbs catalyst, which led to the desired isomer, although all previous steps were 24 
performed on inseparable mixtures of syn- and anti- isomers, with respect to the C4-C5 stereo- centers. The 25 
corresponding anti-isomer was presumably lost in the RCM step. The resulting cis-alkene underwent hydrogenation, 26 
dehydrogenation and deprotection to complete the synthesis.  27 
 28 
2.5.5 Clavilactones (143, 144) 29 
A series of cyclic bioactive compounds, clavilactones A, B and C (144a, 143a and 144b respectively, Figure 7), 30 
were first isolated in 1994 as antifungal and antibacterial constituents in a culture of the non-toxigenic fungus Clitocybe 31 
clavipes.[139] The isolation of structurally related clavilactones D and E (143b and 144c respectively, Figure 7) from 32 
the same fungus, but grown in a different culture medium, has recently been accomplished.[140] Clavilactones A, B and 33 
D have shown potent inhibitory activity toward the epidermal growth factor receptor [104] tyrosine kinase, which is 34 
39 
 
responsible for cellular transduction pathways, thereby underscoring their relevance to medicinal applications.[141] 1 
Clavilactone structures contain a constrained ten-membered ring fused to a 2,3-epoxy-γ-lactone and a benzoquinone or 2 
hydroquinone. In 2006, Barrett et al. [142] reported the total synthesis of ent-clavilactone B ((+)-ent-138a Figure 7) and 3 
the assignment of absolute stereochemistry.  4 
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Scheme 39 Barrett’s synthesis of ent-clavilactone B: a) Bu4NF (TBAF), THF; b) TEMPO (20 mol %), PhI(OAc)2, 7 
DCM (69% two steps); c) Pr4NRuO4 (TPAP) (15 mol %), NMO, 4 Å MS, MeCN, 74%; d) DCM (80%); (e) 8 
Cl2(Cy3P)(sIMes)RudCHPh (40 mol %), tetrafluorobenzoquinone (80 mol %), PhMe, 80 °C (65%); f) CAN, MeCN, 9 
H2O (74%). 10 
 11 
The tri-substituted alkene C11-C12 of clavilactone B was made available by means of a ring closing metathesis reaction 12 
(RCM) from a diene precursor in the presence of Grubbs’ second generation catalyst, in a 65% yield (Scheme 39). The 13 
NMR spectra of the compound obtained were compared with those of a sample derived from the natural product and 14 
complete correlation was found. Consequently, the absolute configuration of the natural product was unambiguously 15 
assigned as 6R, 7R, 8R. The first total synthesis of the natural enantiomers of clavilactones A and B ((+)-144a and (-)-16 
143a respectively Figure 7) was recently accomplished using a conceptually novel method that relies on ring-17 
opening/ring-closing metathesis (ROM/RCM) (Scheme 40).[143]  18 
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Scheme 40 Synthesis of (-)-clavilactone B via ROM/RCM: a) LDA, cyclobuten anhydride, -78 °C to 0 °C (85%); b) i. 21 
1st Grubb’s cat (10 mol %), toluene (0.01 M), 80 °C, 5h. ii. Ethylene (1 atm), 2nd Grubbs Catalysts, 80 °C (76%).  22 
 23 
The one-pot ROM/RCM in toluene using the first-generation Grubbs catalyst, followed by the treatment of the resulting 24 
mixture with ethylene (1 atm) and the second-generation Grubbs catalyst (5 mol %), produced the desired product  in 25 
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good yield (76%). The approach has been also used to synthesize clavilactone A (in 15 steps with 1.6% yield). 1 
Clavilactones A, B, and D have also been synthesized via the iron-catalyzed carbonylation-peroxidation of a 1,5-diene 2 
in three steps .[144]. The synthesis began with a three-component reaction, as shown in Scheme 41, which used FeCl2 3 
as the catalyst. A pyrrolidine-catalyzed epoxidation, followed by a NaBH4-mediated reductive lactonization, furnished 4 
a,b−epoxy-γ-butyrolactones. The chelation between the carbonyl and the epoxy group and the boron atom allows the 5 
hydride to attack the less hindered side of the carbonyl. The total synthesis of (±) clavilactone B was completed in 6 6 
steps and a 15.1 % yield, while 7 steps were needed to give (±) clavilactone A in a 14.9 % yield,and 7 steps again and a 7 
15.5 % yield for (±) the proposed clavilactone D. The total synthesis of clavilactone D allowed the 3-position of the 8 
quinone ring to be established as the correct position of the OH group instead of the 2-position. 9 
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Scheme 41 a) FeCl2, MeCN, 85 °C, 3 h, R=H (60 %), OMe (74 %), OBn (70 %); b) pyrrolidine, MeCN, 0° C, 3 h, R=H 12 
(87%, d.r. 5:1), OMe (90%, d.r. 4:1), OBn (91%, d.r. 4:1); c) NaBH4, EtOH, 0°C, 3 h, R=H (73%), OMe (71%), OBn 13 
(78%). 14 
 15 
An additional synthetic route to clavilactone B features a sequential samarium-mediated radical 16 
cyclization−fragmentation of an indanone derivative, which provides rapid access to a 10-membered carbocyclic motif 17 
fused to an aromatic ring.[145] The approach would provide an alternative to the RCM-based routes that have been 18 
successfully developed so far to synthesize this class of attractive natural product. 19 
 20 
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2.6 LACTAMS 1 
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Figure 8 Chemical structures of the discussed lactams 4 
 5 
 2.6.1 Cytochalasins (146-150) 6 
 Cytochalasins are fungal metabolites that have the ability to bind to actin filaments and inhibit the 7 
polymerization and elongation of actin. As a result of the inhibition of actin polymerization, cytochalasins can change 8 
cellular morphology, inhibit cellular processes, such as cell division, and even cause cells to undergo apoptosis.[146] 9 
The structural series is defined by a largely conserved rigid bicyclic isoindolone core that is fused to a macrocycle (146-10 
150 Figure 8). This last structural component varies widely within cytochalasins and seems to play an important role in 11 
the determination of biological activity. For example, cytochalasin B is an inhibitor of the formation of actin filaments, 12 
while the synthetic 11-membered macrocarbocyclic cytochalasin L has been reported to act as an inhibitor of HIV 13 
protease. Cytochalasins can also have an effect on other aspects of biological processes unrelated to actin 14 
polymerization. For example, cytochalasin A and cytochalasin B can also inhibit the transport of monosaccharides 15 
42 
 
across the cell membrane, cytochalasin H has been found to regulate plant growth, cytochalasin D inhibits protein 1 
synthesis and cytochalasin E prevents angiogenesis.  2 
The complex structures and the extraordinary range of biological activity displayed by cytochalasans have stimulated 3 
many total synthesis programs. Since the synthesis of these challenging mycotoxins has been reviewed 4 
comprehensively by Hertweck and covers the literature up to 2009, we will only provide a short summary of the main 5 
syntheses proposed and the more recent updates.[147]  6 
The first total synthesis of the 14-membered macrolactone, cytochalasin B, by G. Stork and co-workers[148] involves 7 
an intramolecular [4+2] cycloaddition as the key step. Alternative approaches in which the isoindolone core is prepared 8 
first have been proposed. In this context, Trost and co-workers developed a straightforward Pd-catalyzed synthesis to 9 
11-membered cytochalasans, such as aspochalasin B.[149] Haidle and Meyers, however, established a convergent and 10 
highly modular route in order to provide a generally applicable synthetic platform for the preparation of cytochalasans 11 
with varying ring size and substitutions. They synthesized the 14-membered cytochalasin B and the 11-membered 12 
cytochalasin L-696,474. As in the above-mentioned cases, the synthesis starts with the preparation of the isoindolone, 13 
albeit by an alternative intramolecular Diels–Alder reaction.[150] Loh et al. have very recently proposed the synthesis 14 
of a key intermediate to the synthesis of cytochalsins which uses a Lewis acid catalyzed intermolecular Diels-Alder 15 
reaction and multi-functionalized diene and Z-enals to construct six-membered ring systems (Scheme 42).[151] 16 
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Scheme 42 Loh’s synthesis: a) NaClO2, NaH2PO4, t-BuOH, alkene (70%); b) i. TMSCHN2, THF-MeOH, (71%); ii. 20 
LiOH, EtOH-H2O (65%). 21 
 22 
The cytochalasan scaffold is generally reduced to two principal subunits, the isoindolone core and a larger macrocyclic 23 
part, in all the above synthetic approaches.  24 
 25 
 2.6.2 Gymnastatins (151,152) 26 
 Gymnastatin A (151 Figure 8) is a hemiacetal-type natural product, isolated from the strain of Gymnescella 27 
dankaliensis, but originally separated from the sponge Halichondria japonica, together with other gymnastatins.[152] 28 
Gymnastatins have been reported to exhibit significant cytotoxicity against cultured P388 cells. Several members of the 29 
gymnastatin family have shown protein kinase inhibitory activity.[153] Accordingly, their significant bioactivity and 30 
unique structure have meant that several groups have successfully developed synthetic investigations.  31 
This class of fungal derived natural product contains a 4,6-dimethyl-dodecadien-2E,4E-oic acid unit connected to a 32 
tyrosine unit through an amide linkage. The tyrosine unit can have various degrees of oxygenation, halogenation, 33 
cyclisation and esterification, as found in gymnastatin A to H from Gymnastella dankaliensis (151, 152 Figure 8). 34 
These compounds have been reported to have antibacterial and anti-tumor activity.  35 
The total synthesis of gymnastatin A [154], gymnastatin H[152] and gymnastatin I[155] have led to the determination 36 
of their absolute stereochemistry. It currently appears that all of these compounds have a (6R) configuration at the 4,6-37 
dimethyl-dodecadien-2E,4E-oic acid unit.  38 
The first total synthesis of a novel, potent cytotoxic metabolite gymnastatin A was accomplished, in 2000, via the 39 
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oxidative cyclization of a 3,5-dichlorotyrosine derivative.[154] In 2004, Poohn et al. performed the total synthesis of 1 
gymnostatin N (Scheme 43).[156] Four stereoisomers were synthesized, but none of them matched natural gymnostatin 2 
N, which has proven to be a mixture of two stereoisomers, as demonstrated by the same authors. 3 
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Scheme 43 Synthesis of gymnastatin N: a) Wang resin-bound L-Tyr(t-Bu), PyBOP, HOBt, diisopropylethylamine, 7 
anhydrous DMA, rt, 18 h; b) TFA-DCM 1:1, rt, 2 h (93% from step a). 8 
 9 
A different and elegant approach to gymnastatin A was proposed by Nishiyama and colleagues and occurs via the 10 
anodic oxidation of the corresponding phenols, which enabled the synthesis of spiroisoxazoline to be carried out 11 
(Scheme 44). The construction of spiro compounds that bear a hemiacetal moiety and the synthesis of gymnastatin A 12 
were achieved successfully.[157] The anodic oxidation of the substrate was performed in AcOH and gave the 13 
spirodienone compound. In the final step, the hydrolysis of the acetoxy ester in 154 was carried out giving gymnostatin 14 
A. 15 
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Scheme 44 Nishiyama’s synthesis of gymnostatin A: a) anodic oxidation; b) AcOH, cat. H2SO4 aq., 50 °C (84%). 18 
 19 
The asymmetric synthesis of gymnastatin H was achieved using the photoisomerization of a conjugated ester to its β,γ-20 
unsaturated isomer and is in line with environmentally-friendly and more eco-compatible methods. The protonation 21 
onto one of the two diastereotopic faces proceeded well giving very high yields and selectivities thanks to the use of 22 
1,2:5,6-di-O-isopropylidene-α-D-glucofuranose as a chiral alkoxy group. Moreover, the configuration of the C-6 center 23 
of the target molecule was controlled using this method.[158] The total synthesis of (6R)-gymnastatin H was achieved 24 
in 14 steps and in a 4.3% overall yield via the highly diastereoselective photodeconjugation of a diacetone D-glucose 25 
ester, as the key step (de >95%). 26 
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 1 
 2.6.3 Epolactaene (153) 2 
 Epolactaene (153 Figure 8) was isolated as a diastereomeric mixture, at the C-15 position (ca. 5:1 ratio), from the 3 
culture broth of Penicillium sp. BM 1689-P in 1995 by Osada et al.[159] The compound shows potent neurite 4 
outgrowth activity in the human neuroblastoma cell line SH-SY5Y.[160] The structure of 153 was deduced by Osada 5 
using extensive NMR studies including 
1
H-
1
H COSY and HMBC. However, the initial structural assignment did not 6 
allow the absolute stereochemistry of the epoxy moiety to be determined, although it did establish the (E,E,E) geometry 7 
of the conjugated triene and the (E) configuration of the unsaturated ketone. In 1998, Marumoto et al. described the 8 
asymmetric total synthesis of (+)-epolactaene using a convergent approach starting from D-(+)-lactic acid, a C6 unit, 9 
and the Wittig reagent (Scheme 45), which was followed by cyclization to form the lactam ring.[161] 10 
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 13 
Scheme 45 Marumoto’s asymmetric synthesis of (+)-epolactaene: a) i. ZnCl2, ii. LiCH(CO2-t-Bu)2, THF, -78 °C 14 
(53%); b) CF3CO2H, DCM, 0 °C (80%); c) Me3SiCl, imidazole, DMF, 0 °C (94%); d) i. LHMDS, ii. I2, -78 °C; e) 15 
TBAF, THF, -45 to -15 °C (52% two steps); f) HCO2H, rt; g) Me2NH‚HCl, PyBOP, i-Pr2NEt, CH2Cl2, 0 °C (69% two 16 
steps; h) NH3, MeOH, rt; i) TBDMSCl, imidazole, DMF, 0 °C to rt (93% two steps); j) (Z)-Br(CH3)CdCH- (CH2)3OH, 17 
t-BuLi, THF, -78 °C (83%); k) Dess-Martin reagent, DCM, rt (81%). 18 
 19 
The total synthesis of 153 was carried out by Kobayashi et al. in 2003 and relied on an aldol-type condensation of the 20 
epoxylactone which occurred via a two-step procedure from the chiral trimethylsilyl epoxylactone which is derived 21 
from L-xylose.[162] The same synthetic approach was more recently applied by Negishi et al. in 2006 (Scheme 22 
46).[163] In this case, the chiral epoxy lactone was prepared from (S)-3-butyn-2-ol and the synthesis of (+)-epolactaene 23 
was performed using a linear approach consisting of 14 steps. 24 
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 27 
Scheme 46 Negishi’s synthesis of (+)-epolactaene: a) i. TBAF, THF/hexane, ii. HF, MeCN (39% two steps); b) TFAA, 28 
DMSO, Et3N, DCM (85%); c) NH3, MeOH; d) Dess-Martin reagent, DCM (53% two steps).    29 
 30 
Even more recently, a second generation approach to (+)-epolactaene was proposed which makes use of the highly 31 
stereoselective synthesis of the epoxy-γ-lactam moiety via an E-selective Horner-Wadsworth–Emmons reaction and the 32 
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diastereoselective epoxidation of the allyl diol.[164] 1 
 2 
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Figure 9 Chemical structures of the discussed epoxides 7 
 8 
2.7.1 Fumagillin (155), fumagillol (156) and RK-805 (157) 9 
Fumagillin (155 Figure 9) is an antibiotic originally isolated from the microbial organism, Aspergillus fumigatus, 10 
while  also produced by Aspergillus sp, A. flavus and parasiticus.[3]  11 
Concerning its biosynthetic origin, fumagillin derives from both the terpene pathway and the acetate route.[3] It was 12 
first described as an antiparasitic[165] and carcinolytic agent.[166] More recently, it has been discovered that fumagillin 13 
can block blood vessel formation by binding to the enzyme methionine aminopeptidase and, for this reason, the 14 
compound, together with its semisynthetic derivatives, are investigated as an angiogenesis inhibitor in the treatment of 15 
cancer [167] (for recent reviews see ref 192 [168]). Some fumargillin analogues have also been evaluated in human 16 
cancer clinical trials.[3]  17 
The intriguing biological activities of fumagillin and its derivatives have stimulated the interest of several groups. In 18 
fact, many comprehensive reviews have been published on its synthesis since 2003 and up to 2012.[169] The best is 19 
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surely the one written by Yamaguchi and Hayashi in 2010.[169c]  Herein, we would like to highlight a few synthetic 1 
aspects of this pivotal molecule. 2 
Four racemic syntheses, including Corey’s first excellent total syntheses of fumagillin, have been reported.[170] 3 
Diastereoselective syntheses of fumagillin using chiral auxiliaries have been reported by Sorensen.[171] A more 4 
flexible approach to the fumagillin core, using a diastereoselective asymmetric catalytic total synthesis and the proline-5 
mediated a-aminoxylation of carbonyl compounds as the key step, was proposed in 2006 by Hayashi et al. (Scheme 6 
47).[172]. In summary, the reaction proceeds via the following principal transformations: 1) the highly 7 
diastereoselective formation of bis(trimethylsilyl ether) cyanide involving kinetic discrimination; 2) a diastereoselective 8 
Michael reaction using vinyl zincate; 3) a stereoselective double epoxidation catalyzed by VO(OiPr)3 at low 9 
temperature; 4) an alkylative deprotection of an oxime. 10 
 11 
O
O
OH
O H 157
O O
O
a
O O
O
OR
R
 = NHPh
R
 = H
b
O O
OTMS
NC OH
O O
OTMS
OHC OH OHTBSO
Br
f
O
OHTBSO
OTMS
g
OHTBSO
O
OH
c d e
h i j 156 k 155
 12 
Scheme 47 Hayashi’s synthesis of fumagillin: a) L-prolin (10%), Ph-N=O, DMF 0° C, 24 h (93%, > 99% ee); b) Pd/C, 13 
H2 (90%); c) TMSCN, cat. Et3N, DCM (68% yield, > 95:5 dr); d) DIBAL-H, Et2O, - 60 °C to -30 °C (72%); e) i. 14 
DIBAL-H, DCM, ii. Amberlyst-15, THF, 60 °C, iii. TBSCl, Et3N cat. DMAP, DCM (57% over 3 steps); f) t-BuLi, 15 
Me2N2, THF, -78 °C to -40 °C, 2h then TMSCl, Et3N -40 °C to -20 °C, 1 h (61 %, > 95:5 dr); g) i. DMD, MeOH, -90 16 
°C, ii. TBAF, THF (74% yield, 95:5); h) i. cat Vo(acac)2, TBHP, DCM, ii. K2CO3, MeOH (75%, 95:5 dr); i) MeI, 17 
Ag2O, MeCN; j) K-selectride (94%, > 95:5 dr); k) see ref .172 18 
 19 
 2.7.2 Epiepoxydon (159), Epiepoformin (158a) and Bromoxone (158b) 20 
  Epiepoxydon (159 Figure 9) and related compounds are well known as typical oxygenated cyclohexenones with 21 
remarkable biological activiy. Epiepoxydon was isolated from the culture broth of an unidentified fungus separated 22 
from a diseased crapemyrtle leaf by Nagasawa and co-workers in 1978.[173] The acetate of bromoxone (158b Figure 9) 23 
shows potent antitumor activity against P388 cells in vitro.[174] Several methods for their synthesis have already been 24 
reported.[175] In 2003, Tachihara and Kitahara described novel syntheses of epiepoformin, epiepoxydon and 25 
bromoxone using a common chiral building block; ethyl (1R,2S)-5,5-ethylenedioxy-2-26 
hydroxycyclohexanecarboxylate.[175b] A simple enzyme mediated strategy to access chiral building blocks for the 27 
synthesis of a range of biologically active epoxyquinone natural products from readily available starting materials was 28 
proposed by Metha and coworkers.[176]  29 
The levorotatory enantiomer of epiepoxidon has recently been prepared. The approach relies on the initial 30 
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desymmetrization of p-methoxyphenol, followed by an enzymatic resolution that separately provides the two 1 
enantiomers of a key synthon.[177] The first synthesis of (-)-epiepoxydon was then accomplished from a simple 2 
precursor, in six steps with a 40 % overall yields (Scheme 48). 3 
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Scheme 48 Synthesis of (-)-epiepoxydon: a) HCHO, t-BuOK (88%); b) Ac2O, Py (99%); c) t-BuOOH, Triton B (76%); 7 
d) MCPBA, CHCl3; e) Et3N, HF; f) CALB, i-Pr2O (75%). 8 
 9 
 2.7.3 Epoxyquinols (160,161) 10 
 Of the members of the family of natural compounds bearing the epoxyquinol moiety, shown in Figure 9, 11 
epoxyquinol A and B are worthy of mention. They were synthesized by Metha et al. [178] from the readily available 12 
Diels–Alder adduct between cyclopentadiene and p-benzoquinone (Scheme 49).  13 
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Scheme 49 Metha’s synthesis of epoxyquinols: a) DIBAL-H, THF, -78°C (74%); b) Dess-Martin periodinane, PPTS, 16 
acetone, rt (89%); c) NaBH4, CeCl3/H2O, MeOH, 0°C (86%); d) K2CO3, MeOH, 0°C (74%); e) TEMPO, O2, CuCl, 17 
DMF (76%); f) C2H5PPh3Br, n-BuLi, THF, 0 °C; g) Amberlyst 15, MeOH, rt (79%); h) TEMPO, O2 , CuCl, DMF, rt; i) 18 
neat,  30 °C, 8 h,  (160 48% and (161 18%). 19 
 20 
Porco performed the synthesis of epoxyquinols A and B and a number of related compounds using [4 + 2] and [4 + 4] 21 
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dimerizations of 2H-pyran epoxyquinol monomers. Modifications to 2H-pyran precursors have been explored and 1 
include the alteration of epoxy alcohol and diene stereochemistry.[179] An asymmetric total synthesis of the novel 2 
epoxyquinol natural product (+)-panepophenanthrin has been accomplished following this synthetic approach and using 3 
a biomimetic Diels–Alder dimerisation is the key step. The key monomeric precursor was assembled via the efficient 4 
Stille cross coupling of two readily available building blocks that, upon standing, underwent a diastereospecific 5 
dimerization cascade in excellent yield.[180] 6 
 7 
2.7.4 Cycloepoxydon (162) 8 
Cycloepoxydon (157 Figure 9) has been isolated from a deuteromycete strain [181] and has been shown to inhibit 9 
the activation of NF-κB, an inducible, ubiquitous transcription factor that regulates the expression of various cellular 10 
genes involved in immune and inflammation responses and apoptosis.[182] Metha carried out the enantioselective total 11 
synthesis of (-)-cycloepoxydon using a readily available Diels-Alder adduct of cyclopentadiene and p-12 
benzoquinone.[183]. 13 
 14 
2.7.5 Panepoxydone (163) 15 
Structurally related to cycliepoxydone, panepoxydone (163 Figure 9) has been isolated from basidiomycete 16 
conchatus [182] and reported to exhibit potent NF-B inhibitory activity.[184] Efficient strategies for producing, these 17 
and other, congeners via total synthesis have been proposed. In 2000, Wood and colleagues described the first total 18 
synthesis of panepoxydone along with the correction of the absolute configuration originally assigned.[185] Structure-19 
activity relationship studies of this class of compound have also been reported.[186] 20 
 21 
3. Conclusion 22 
Fungi have always been a rich source of effective drugs and are still an important source for the identification of 23 
new pharmacological leads today. Renewed scientific interest in the drug discovery of fungi-derived natural products is 24 
evident in a huge number of publications in this field. As a consequence, new approaches to the identification, 25 
characterization and resupply of natural products are highly desirable. These may address some of the challenges related 26 
to the development of fungi-based therapeutics. Resupply from the original fungal species is often too unfeasible to 27 
meet market demands upon commercialization of a natural product. Moreover, alternative resupply approaches, which 28 
relying on biotechnological production or chemical synthesis, are being developed. In this review, we have 29 
demonstrated that total chemical synthesis is an effective resupply strategy. As an alternative, the improvement of 30 
knowledge on fungi biosynthetic pathways will facilitate the development of more efficient genetic engineering 31 
strategies and tools. Research trends clearly indicate that natural products will be among the most important sources of 32 
new drugs in the future. However, their full potential will only be realized through a highly integrated interdisciplinary 33 
approach made possible by recent advances in technology and knowledge. 34 
 35 
 36 
LIST OF ABBREVIATIONS 37 
Acac = Acetylacetonato 38 
AcOH = Acetic acid 39 
AIBN = 2,2′-Azobis(2-methylpropionitrile) 40 
49 
 
Alloc = Allyloxycarbonyl 1 
(S)-BINAP = (S)-2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene  2 
Bn = Benzyl 3 
Boc = tert-Butoxycarbonyl 4 
BOP-Cl = bis(2-oxo-3-oxazolidinyl)phosphonyl chloride 5 
9-BBN = 9-Borabicyclo[3.3.1]nonane  6 
CAN = Cerium Ammonium Nitrate 7 
CALB = Candida Antarctica Lipase B  8 
Cp = Pentamethylcyclopentadienyl 9 
m-CPBA = m-Chloroperbenzoic acid 10 
(+)-CSA = (+)-10-Camphorosulfonic acid 11 
DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene 12 
DCC = N,N'-Dicyclohexylcarbodiimide 13 
DCE = Dichloroethane 14 
DCM = Dichloromethane 15 
DDQ = 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 16 
DIBAL-H = Diisobutylaluminium hydride 17 
DIPEA = N,N-Diisopropylethylamine 18 
L-DIPT = (+)-Diisopropyl L-tartrate 19 
DMA = N,N-Dimethylacetamide 20 
DMAP = 4-Dimethylaminopyridine 21 
DMAPP = Dimethyallyl pyrophosphate 22 
DMD = 5,6-Dimethyl-1H-benzimidazole 23 
DMDO = Dimethyldioxirane 24 
DMF = N,N-dimethylformamide 25 
DMSO = Dimethyl sulfoxide 26 
EDC HCl = Nʹ-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 27 
HATU = 2-(1-H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium 28 
HMDS = Bis(trimethylsilyl)amide  29 
HOAt = 1-Hydroxy-7-azabenzotriazole 30 
HOBt = 1-Hydroxybenzotriazole 31 
IBX = 2-Iodoxybenzoic acid 32 
LDA = Lithium diisopropylamide 33 
MNBA = 2-Methyl-6-nitrobenzoic anhydride 34 
NBS = N-Bromosuccunimide 35 
NMO = N-methylmorpholine-N-oxide 36 
NMM = N-methylmorpholine 37 
nor-AZADO = 9-Azanoradamantane-N-oxyl 38 
MOMCl = Methoxymethyl chloride 39 
PCC = Pyridinium chlorochromate 40 
PDC = Pyridinium dichromate  41 
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PPTS = Pyridinium p-toluenesulfonate 1 
Pyr = Pyridine 2 
PyBOP = (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 3 
TASF = Tris(dimethylamino)sulfur trimethylsilyl difluoride 4 
TBAA = Tetrabutylammonium acetate 5 
TBAB = Tetrabutylammonium bromide 6 
TBAF = Tetrabutylammonium fluoride 7 
TBAOH = Tetrabutylammonium hydroxide 8 
TBDMSCl = tert-Butyldimethylsilyl chloride 9 
TBDPS = tert-Butyldiphenylsilyl 10 
TBHP = tert-Butyl hydroperoxide 11 
TBS = tert-Butyldimethylsilyl 12 
TEMPO = 2,2,6,6-Tetramethylpiperidin-1-yloxy 13 
TESCl = Triethysilyl chloride 14 
Tf = Triflate (trifluoromethanesulfonate) 15 
TFA= Trifluoroacetic acid 16 
TFAA = Trifluoroacetic anhydride 17 
THF = Tetrahydrofuran 18 
TIPSOTf = Triisopropylsilyl trifluoromethanesulfonate 19 
TMEDA = N,N,Nʹ,Nʹ-Tetramethylethylenediamine 20 
TMP = 2,2,6,6-Tetramethylpiperidine 21 
TMSCHN2 = Trimethylsilyl diazomethane 22 
TMSCN = Trimethylsilyl cyanide 23 
TMSI = Trimethylsilyl iodide 24 
TMSOTf = Trimethylsilyl trifluoromethanesulfonate 25 
TPAP = Tetrapropylammonium perruthenate 26 
Ts = Tosyl 27 
TrSSSCl = Chloro(triphenylmethyl) trisulfane 28 
SEMCl = 2-(Trimethylsilyl)ethoxymethyl chloride 29 
WSCD = Water soluble carbodiimide 30 
 31 
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